|
G |
ABCC1 |
ATP binding cassette subfamily C member 1 |
decreases activity |
EXP |
chrysoeriol results in decreased activity of ABCC1 protein |
CTD |
PMID:15670588 |
|
NCBI chr16:15,949,616...16,143,062
Ensembl chr16:15,949,577...16,143,074 Ensembl chr16:15,949,577...16,143,074
|
|
G |
AHR |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
chrysoeriol inhibits the reaction [Benzo(a)pyrene binds to AHR protein] |
CTD |
PMID:20553787 |
|
NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152
|
|
G |
BGLAP |
bone gamma-carboxyglutamate protein |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [Hydrogen Peroxide results in decreased expression of BGLAP protein] |
CTD |
PMID:20981859 |
|
NCBI chr 1:156,242,184...156,243,317
Ensembl chr 1:156,242,184...156,243,317
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
multiple interactions |
EXP |
chrysoeriol inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:20553787 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
multiple interactions |
EXP |
chrysoeriol inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA] |
CTD |
PMID:20553787 |
|
NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
multiple interactions |
EXP |
chrysoeriol inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA] |
CTD |
PMID:20553787 |
|
NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [Hydrogen Peroxide results in increased expression of IL6 protein] |
CTD |
PMID:20981859 |
|
NCBI chr 7:22,725,889...22,732,002
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
MTNR1A |
melatonin receptor 1A |
affects binding |
EXP |
chrysoeriol binds to MTNR1A protein |
CTD |
PMID:20399199 |
|
NCBI chr 4:186,532,769...186,555,567
Ensembl chr 4:186,533,655...186,555,567
|
|
G |
MTNR1B |
melatonin receptor 1B |
affects binding |
EXP |
chrysoeriol binds to MTNR1B protein |
CTD |
PMID:20399199 |
|
NCBI chr11:92,969,651...92,986,241
Ensembl chr11:92,969,651...92,985,066 Ensembl chr11:92,969,651...92,985,066
|
|
G |
NQO2 |
N-ribosyldihydronicotinamide:quinone reductase 2 |
multiple interactions |
EXP |
chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of 1-benzyl-1,4-dihydronicotinamide] which results in increased reduction of Ubiquinone Q2]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of 1-benzyl-1,4-dihydronicotinamide] which results in increased reduction of Vitamin K 3]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3] |
CTD |
PMID:20399199 |
|
NCBI chr 6:2,999,894...3,019,755
Ensembl chr 6:2,987,987...3,021,850 Ensembl chr 6:2,987,987...3,021,850
|
|
G |
TNFSF11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [Hydrogen Peroxide results in increased expression of TNFSF11 protein] |
CTD |
PMID:20981859 |
|
NCBI chr13:42,562,736...42,608,013
Ensembl chr13:42,562,736...42,608,013
|
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
multiple interactions increases chemical synthesis |
EXP |
[CYP1A1 protein affects the metabolism of scutellarein] which results in increased chemical synthesis of 6-hydroxyluteolin CYP1A1 protein results in increased chemical synthesis of 6-hydroxyluteolin |
CTD |
PMID:19666078 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
increases chemical synthesis multiple interactions |
EXP |
CYP1B1 protein results in increased chemical synthesis of 6-hydroxyluteolin [CYP1B1 protein affects the metabolism of scutellarein] which results in increased chemical synthesis of 6-hydroxyluteolin |
CTD |
PMID:19666078 |
|
NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902
|
|
|
G |
MITF |
melanocyte inducing transcription factor |
increases expression |
EXP |
afzelin results in increased expression of MITF mRNA; afzelin results in increased expression of MITF protein |
CTD |
PMID:27287415 |
|
NCBI chr 3:69,739,464...69,968,332
Ensembl chr 3:69,739,464...69,968,336 Ensembl chr 3:69,739,464...69,968,336
|
|
G |
TYR |
tyrosinase |
multiple interactions increases expression |
EXP |
afzelin results in increased expression of and results in increased activity of TYR protein afzelin results in increased expression of TYR mRNA |
CTD |
PMID:27287415 |
|
NCBI chr11:89,177,565...89,295,759
Ensembl chr11:89,177,875...89,295,759
|
|
G |
TYRP1 |
tyrosinase related protein 1 |
increases expression |
EXP |
afzelin results in increased expression of TYRP1 mRNA; afzelin results in increased expression of TYRP1 protein |
CTD |
PMID:27287415 |
|
NCBI chr 9:12,693,375...12,710,285
Ensembl chr 9:12,685,439...12,710,285
|
|
|
G |
ABCC1 |
ATP binding cassette subfamily C member 1 |
decreases activity |
EXP |
diosmetin results in decreased activity of ABCC1 protein |
CTD |
PMID:15670588 |
|
NCBI chr16:15,949,616...16,143,062
Ensembl chr16:15,949,577...16,143,074 Ensembl chr16:15,949,577...16,143,074
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
decreases activity |
EXP |
diosmetin results in decreased activity of CYP1A1 protein |
CTD |
PMID:10781868 PMID:21482471 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
decreases activity |
EXP |
diosmetin results in decreased activity of CYP1A2 protein |
CTD |
PMID:28867436 |
|
NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
decreases activity |
EXP |
diosmetin results in decreased activity of CYP1B1 protein |
CTD |
PMID:10781868 PMID:21482471 |
|
NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902
|
|
G |
CYP2C19 |
cytochrome P450 family 2 subfamily C member 19 |
decreases activity |
EXP |
diosmetin results in decreased activity of CYP2C19 protein |
CTD |
PMID:28867436 |
|
NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547
|
|
G |
CYP2C8 |
cytochrome P450 family 2 subfamily C member 8 |
decreases activity |
EXP |
diosmetin results in decreased activity of CYP2C8 protein |
CTD |
PMID:28867436 |
|
NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497
|
|
G |
CYP2C9 |
cytochrome P450 family 2 subfamily C member 9 |
decreases activity |
EXP |
diosmetin results in decreased activity of CYP2C9 protein |
CTD |
PMID:28867436 |
|
NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
decreases activity |
EXP |
diosmetin results in decreased activity of CYP2E1 protein |
CTD |
PMID:28867436 |
|
NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
multiple interactions |
EXP |
diosmetin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; diosmetin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam] |
CTD |
PMID:18191104 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
CYP3A5 |
cytochrome P450 family 3 subfamily A member 5 |
multiple interactions |
EXP |
diosmetin inhibits the reaction [CYP3A5 protein results in increased chemical synthesis of 4-hydroxymidazolam] |
CTD |
PMID:18191104 |
|
NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,998
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
multiple interactions |
ISO |
diosmetin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:16934226 |
|
NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,511...35,404,749 Ensembl chr14:35,401,511...35,404,749
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:16934226 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
PKM |
pyruvate kinase M1/2 |
increases activity |
EXP |
diosmetin results in increased activity of PKM protein |
CTD |
PMID:25388478 |
|
NCBI chr15:72,199,029...72,231,389
Ensembl chr15:72,199,029...72,231,822
|
|
G |
SLC16A1 |
solute carrier family 16 member 1 |
multiple interactions |
ISO |
[diosmetin results in decreased activity of SLC16A1 protein] which results in decreased uptake of Sodium Oxybate |
CTD |
PMID:17108059 |
|
NCBI chr 1:112,911,847...112,956,196
Ensembl chr 1:112,911,847...112,957,013
|
|
G |
SLC22A1 |
solute carrier family 22 member 1 |
multiple interactions |
EXP |
diosmetin inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:28867436 |
|
NCBI chr 6:160,121,808...160,160,590
Ensembl chr 6:160,121,815...160,158,718
|
|
G |
SLCO1A2 |
solute carrier organic anion transporter family member 1A2 |
multiple interactions |
EXP |
diosmetin inhibits the reaction [SLCO1A2 protein results in increased uptake of Rosuvastatin Calcium] |
CTD |
PMID:28867436 |
|
NCBI chr12:21,264,600...21,419,634
Ensembl chr12:21,264,600...21,419,594
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
ISO |
diosmetin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:16934226 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
|
G |
AHR |
aryl hydrocarbon receptor |
multiple interactions |
ISO EXP |
Diosmin binds to and results in increased activity of AHR protein |
CTD |
PMID:14644660 |
|
NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152
|
|
G |
BAD |
BCL2 associated agonist of cell death |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Lipopolysaccharides results in increased expression of BAD protein] |
CTD |
PMID:21477647 |
|
NCBI chr11:64,269,828...64,284,704
Ensembl chr11:64,269,830...64,284,704
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of BAX protein] |
CTD |
PMID:32061149 |
|
NCBI chr19:48,954,825...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions |
ISO |
[Diosmin co-treated with Lipopolysaccharides] results in increased expression of BCL2 protein Diosmin inhibits the reaction [Benzo(a)pyrene results in decreased expression of BCL2 protein] |
CTD |
PMID:21477647 PMID:32061149 |
|
NCBI chr18:63,123,346...63,320,280
Ensembl chr18:63,123,346...63,320,128
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of CASP3 protein]; Diosmin inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in increased cleavage of CASP3 protein] |
CTD |
PMID:21477647 PMID:23665045 PMID:32061149 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
|
|
G |
CASP7 |
caspase 7 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of CASP7 protein] |
CTD |
PMID:23665045 |
|
NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907
|
|
G |
CASP9 |
caspase 9 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of CASP9 protein] |
CTD |
PMID:23665045 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in decreased expression of CAT protein]; Diosmin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein] |
CTD |
PMID:22056647 PMID:23665045 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of CYP2E1 protein] |
CTD |
PMID:23665045 |
|
NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220
|
|
G |
GSR |
glutathione-disulfide reductase |
multiple interactions |
ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in decreased expression of GSR protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in decreased expression of GSR protein] |
CTD |
PMID:23665045 PMID:32061149 |
|
NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of IL6 protein] |
CTD |
PMID:32061149 |
|
NCBI chr 7:22,725,889...22,732,002
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
MKI67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of MKI67 protein]; Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of MKI67 protein] |
CTD |
PMID:23665045 |
|
NCBI chr10:128,096,659...128,126,423
Ensembl chr10:128,096,659...128,126,423
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of NOS2 protein] |
CTD |
PMID:23665045 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased cleavage of PARP1 protein] |
CTD |
PMID:32061149 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,691...226,408,093 Ensembl chr 1:226,360,691...226,408,093
|
|
G |
PCNA |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of PCNA protein]; Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of PCNA protein] |
CTD |
PMID:23665045 |
|
NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of PTGS2 protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of PTGS2 protein] |
CTD |
PMID:23665045 PMID:32061149 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,423
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of RELA protein] |
CTD |
PMID:32061149 |
|
NCBI chr11:65,653,601...65,662,946
Ensembl chr11:65,653,597...65,663,090
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of TNF protein]; Diosmin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:21477647 PMID:23665045 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of TP53 protein] |
CTD |
PMID:23665045 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538 Ensembl chr17:7,661,779...7,687,538
|
|
G |
XDH |
xanthine dehydrogenase |
multiple interactions |
ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of XDH protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of XDH protein] |
CTD |
PMID:23665045 PMID:32061149 |
|
NCBI chr 2:31,334,320...31,414,777
Ensembl chr 2:31,334,321...31,414,742
|
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
increases response to substance increases metabolic processing decreases activity increases expression |
EXP |
CYP1A1 protein results in increased susceptibility to eupatorin CYP1A1 protein results in increased metabolism of eupatorin analog eupatorin analog results in decreased activity of CYP1A1 protein eupatorin results in increased expression of CYP1A1 mRNA |
CTD |
PMID:18454852 PMID:19601638 PMID:21482471 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
increases metabolic processing increases expression decreases activity |
EXP |
CYP1B1 protein results in increased metabolism of eupatorin analog eupatorin results in increased expression of CYP1B1 mRNA eupatorin results in decreased activity of CYP1B1 protein |
CTD |
PMID:19601638 PMID:21482471 |
|
NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902
|
|
G |
CYP2C19 |
cytochrome P450 family 2 subfamily C member 19 |
decreases activity |
EXP |
eupatorin results in decreased activity of CYP2C19 protein |
CTD |
PMID:21093571 |
|
NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547
|
|
G |
CYP2D6 |
cytochrome P450 family 2 subfamily D member 6 |
decreases activity |
EXP |
eupatorin results in decreased activity of CYP2D6 protein |
CTD |
PMID:21276781 |
|
NCBI chr22:42,126,499...42,130,810
Ensembl chr22:42,126,499...42,130,881
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
decreases activity |
EXP |
eupatorin results in decreased activity of CYP3A4 protein |
CTD |
PMID:21276781 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
|
G |
AFP |
alpha fetoprotein |
affects binding |
ISO |
fisetin binds to AFP protein |
CTD |
PMID:23013281 PMID:25349334 |
|
NCBI chr 4:73,436,221...73,456,174
Ensembl chr 4:73,431,138...73,456,174
|
|
G |
AIFM1 |
apoptosis inducing factor mitochondria associated 1 |
increases localization |
EXP |
fisetin results in increased localization of AIFM1 protein |
CTD |
PMID:28181380 |
|
NCBI chr X:130,129,362...130,165,841
Ensembl chr X:130,124,666...130,165,879 Ensembl chr X:130,124,666...130,165,879
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO EXP |
fisetin results in increased phosphorylation of AKT1 protein fisetin inhibits the reaction [Oxygen deficiency results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:20153296 PMID:25428606 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
|
|
G |
APP |
amyloid beta precursor protein |
multiple interactions |
ISO |
fisetin inhibits the reaction [Lead results in increased expression of APP protein] |
CTD |
PMID:31539617 |
|
NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,550...26,171,128
|
|
G |
AR |
androgen receptor |
multiple interactions decreases expression |
EXP |
fisetin inhibits the reaction [Dihydrotestosterone results in increased expression of AR protein]; fisetin inhibits the reaction [Metribolone results in increased folding of and results in increased stability of AR protein]; fisetin results in decreased stability of and results in decreased expression of AR protein fisetin results in decreased expression of AR mRNA |
CTD |
PMID:18922931 |
|
NCBI chr X:67,544,021...67,730,619
Ensembl chr X:67,544,021...67,730,619
|
|
G |
ATF6 |
activating transcription factor 6 |
increases expression multiple interactions |
EXP |
fisetin results in increased expression of ATF6 protein 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [fisetin results in increased expression of ATF6 protein] |
CTD |
PMID:28181380 |
|
NCBI chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,320...161,964,070
|
|
G |
ATF6B |
activating transcription factor 6 beta |
multiple interactions increases expression |
EXP |
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [fisetin results in increased expression of ATF6B protein] |
CTD |
PMID:28181380 |
|
NCBI chr 6:32,115,264...32,128,246
Ensembl chr 6:32,115,264...32,128,253
|
|
G |
BAK1 |
BCL2 antagonist/killer 1 |
multiple interactions |
EXP |
[Cisplatin co-treated with fisetin] results in increased expression of BAK1 protein |
CTD |
PMID:21216935 |
|
NCBI chr 6:33,572,552...33,580,296
Ensembl chr 6:33,572,547...33,580,293
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression affects expression |
ISO EXP |
fisetin inhibits the reaction [Cisplatin results in increased expression of BAX protein] fisetin results in increased expression of BAX protein fisetin inhibits the reaction [Lead results in increased expression of BAX protein] fisetin affects the expression of BAX protein [fisetin co-treated with Paclitaxel] results in increased expression of BAX mRNA; [U 0126 co-treated with pyrazolanthrone] inhibits the reaction [fisetin results in increased expression of BAX protein]; [XMU-MP-1 co-treated with U 0126 co-treated with pyrazolanthrone] inhibits the reaction [fisetin results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [fisetin results in increased expression of BAX protein]; U 0126 inhibits the reaction [fisetin results in increased expression of BAX protein]; XMU-MP-1 inhibits the reaction [fisetin results in increased expression of BAX protein] |
CTD |
PMID:25184746 PMID:26884726 PMID:28181380 PMID:31044527 PMID:31539617 |
|
NCBI chr19:48,954,825...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions decreases expression |
ISO EXP |
fisetin inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein] fisetin inhibits the reaction [Lead results in decreased expression of BCL2 protein] fisetin results in decreased expression of BCL2 protein [fisetin co-treated with Paclitaxel] results in increased expression of BCL2 mRNA |
CTD |
PMID:25184746 PMID:26884726 PMID:28181380 PMID:31539617 |
|
NCBI chr18:63,123,346...63,320,280
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BCL2L1 |
BCL2 like 1 |
multiple interactions decreases expression |
EXP |
[pyrazolanthrone co-treated with U 0126] inhibits the reaction [fisetin results in decreased expression of BCL2L1 protein]; [XMU-MP-1 co-treated with pyrazolanthrone co-treated with U 0126] inhibits the reaction [fisetin results in decreased expression of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [fisetin results in decreased expression of BCL2L1 protein]; U 0126 inhibits the reaction [fisetin results in decreased expression of BCL2L1 protein]; XMU-MP-1 inhibits the reaction [fisetin results in decreased expression of BCL2L1 protein] |
CTD |
PMID:31044527 |
|
NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
|
|
G |
BDNF |
brain derived neurotrophic factor |
multiple interactions |
ISO |
fisetin inhibits the reaction [methylmercuric chloride results in decreased expression of BDNF protein] |
CTD |
PMID:30890323 |
|
NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058
|
|
G |
BECN1 |
beclin 1 |
multiple interactions |
ISO |
fisetin promotes the reaction [Lead results in increased expression of BECN1 protein] |
CTD |
PMID:31539617 |
|
NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350
|
|
G |
BID |
BH3 interacting domain death agonist |
multiple interactions affects expression increases cleavage |
EXP |
[Cisplatin co-treated with fisetin] results in increased cleavage of BID protein fisetin affects the expression of BID protein fisetin results in increased cleavage of BID protein |
CTD |
PMID:21216935 PMID:28181380 |
|
NCBI chr22:17,734,138...17,774,665
Ensembl chr22:17,734,138...17,774,770
|
|
G |
BIRC5 |
baculoviral IAP repeat containing 5 |
multiple interactions |
EXP |
[Cisplatin co-treated with fisetin] results in decreased expression of BIRC5 protein |
CTD |
PMID:21216935 |
|
NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636
|
|
G |
CAPN1 |
calpain 1 |
increases expression multiple interactions |
EXP |
fisetin results in increased expression of CAPN1 protein 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [fisetin results in increased expression of CAPN1 protein] |
CTD |
PMID:28181380 |
|
NCBI chr11:65,181,373...65,212,006
Ensembl chr11:65,180,566...65,212,006
|
|
G |
CAPN2 |
calpain 2 |
multiple interactions increases expression |
EXP |
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [fisetin results in increased expression of CAPN2 protein] |
CTD |
PMID:28181380 |
|
NCBI chr 1:223,701,597...223,776,018
Ensembl chr 1:223,701,593...223,776,018
|
|
G |
CASP12 |
caspase 12 (gene/pseudogene) |
increases expression multiple interactions |
EXP |
fisetin results in increased expression of CASP12 protein 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [fisetin results in increased expression of CASP12 protein] |
CTD |
PMID:28181380 |
|
NCBI chr11:104,885,718...104,898,460
Ensembl chr11:104,885,718...104,898,670
|
|
G |
CASP3 |
caspase 3 |
multiple interactions increases cleavage increases activity |
EXP ISO |
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [fisetin results in increased activity of CASP3 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [fisetin results in increased activity of CASP3 protein]; [Cisplatin co-treated with fisetin] results in increased cleavage of and results in increased activity of CASP3 protein; [fisetin co-treated with Paclitaxel] results in increased expression of CASP3 mRNA; [U 0126 co-treated with pyrazolanthrone] inhibits the reaction [fisetin results in increased cleavage of CASP3 protein]; [XMU-MP-1 co-treated with U 0126 co-treated with pyrazolanthrone] inhibits the reaction [fisetin results in increased cleavage of CASP3 protein]; fisetin inhibits the reaction [Silicon Dioxide results in increased expression of CASP3 mRNA]; pyrazolanthrone inhibits the reaction [fisetin results in increased cleavage of CASP3 protein]; U 0126 inhibits the reaction [fisetin results in increased cleavage of CASP3 protein]; XMU-MP-1 inhibits the reaction [fisetin results in increased cleavage of CASP3 protein] fisetin inhibits the reaction [Lead results in increased cleavage of CASP3 protein] fisetin inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein] |
CTD |
PMID:21216935 PMID:21964635 PMID:22931364 PMID:25184746 PMID:26884726 PMID:28181380 PMID:31044527 PMID:31539617 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
|
|
G |
CASP4 |
caspase 4 |
multiple interactions increases expression |
EXP |
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [fisetin results in increased expression of CASP4 protein] |
CTD |
PMID:28181380 |
|
NCBI chr11:104,942,866...104,968,596
Ensembl chr11:104,942,866...104,969,366
|
|
G |
CASP7 |
caspase 7 |
multiple interactions |
EXP |
[Cisplatin co-treated with fisetin] promotes the reaction [CASP9 protein results in increased cleavage of CASP7 protein]; fisetin promotes the reaction [CASP9 protein results in increased cleavage of CASP7 protein] |
CTD |
PMID:21216935 |
|
NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907
|
|
G |
CASP8 |
caspase 8 |
multiple interactions increases activity |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [fisetin results in increased activity of CASP8 protein]; [Cisplatin co-treated with fisetin] results in increased cleavage of and results in increased activity of CASP8 protein; fisetin results in increased cleavage of and results in increased activity of CASP8 protein |
CTD |
PMID:21216935 PMID:21964635 PMID:28181380 |
|
NCBI chr 2:201,233,443...201,287,711
Ensembl chr 2:201,233,443...201,287,711
|
|
G |
CASP9 |
caspase 9 |
multiple interactions increases activity |
EXP ISO |
[Cisplatin co-treated with fisetin] promotes the reaction [CASP9 protein results in increased cleavage of CASP7 protein]; [Cisplatin co-treated with fisetin] results in increased cleavage of and results in increased activity of CASP9 protein; fisetin promotes the reaction [CASP9 protein results in increased cleavage of CASP7 protein]; fisetin results in increased cleavage of and results in increased activity of CASP9 protein fisetin results in increased activity of CASP9 protein fisetin inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein] |
CTD |
PMID:21216935 PMID:25184746 PMID:28181380 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
fisetin inhibits the reaction [Cisplatin results in decreased activity of CAT protein] |
CTD |
PMID:25184746 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCN2 |
cellular communication network factor 2 |
multiple interactions decreases expression |
EXP |
[pyrazolanthrone co-treated with U 0126] inhibits the reaction [fisetin results in decreased expression of CCN2 protein]; [XMU-MP-1 co-treated with pyrazolanthrone co-treated with U 0126] inhibits the reaction [fisetin results in decreased expression of CCN2 protein]; pyrazolanthrone inhibits the reaction [fisetin results in decreased expression of CCN2 protein]; U 0126 inhibits the reaction [fisetin results in decreased expression of CCN2 protein]; XMU-MP-1 inhibits the reaction [fisetin results in decreased expression of CCN2 protein] |
CTD |
PMID:31044527 |
|
NCBI chr 6:131,948,176...131,951,372
Ensembl chr 6:131,948,176...131,951,372
|
|
G |
CCNA2 |
cyclin A2 |
decreases expression |
EXP |
fisetin results in decreased expression of CCNA2 protein |
CTD |
PMID:28181380 |
|
NCBI chr 4:121,816,444...121,823,883
Ensembl chr 4:121,816,444...121,823,883 Ensembl chr 4:121,816,444...121,823,883
|
|
G |
CCNB1 |
cyclin B1 |
multiple interactions decreases expression |
EXP |
[Cisplatin co-treated with fisetin] results in decreased expression of CCNB1 protein fisetin results in decreased expression of CCNB1 protein |
CTD |
PMID:21216935 PMID:28181380 |
|
NCBI chr 5:69,167,150...69,178,245
Ensembl chr 5:69,167,135...69,178,245
|
|
G |
CD40 |
CD40 molecule |
multiple interactions |
EXP |
fisetin inhibits the reaction [[Calcimycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CD40 protein] |
CTD |
PMID:16601352 |
|
NCBI chr20:46,118,242...46,129,858
Ensembl chr20:46,118,278...46,129,863
|
|
G |
CD44 |
CD44 molecule (Indian blood group) |
decreases expression |
EXP |
fisetin results in decreased expression of CD44 protein |
CTD |
PMID:30802432 |
|
NCBI chr11:35,139,168...35,232,402
Ensembl chr11:35,138,882...35,232,402 Ensembl chr11:35,138,882...35,232,402
|
|
G |
CDC25C |
cell division cycle 25C |
decreases expression |
EXP |
fisetin results in decreased expression of CDC25C protein |
CTD |
PMID:28181380 |
|
NCBI chr 5:138,285,265...138,338,355
Ensembl chr 5:138,285,265...138,338,355
|
|
G |
CDH1 |
cadherin 1 |
increases expression multiple interactions |
EXP |
fisetin results in increased expression of CDH1 protein fisetin inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of CDH1 protein]; fisetin inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of CDH1 protein] |
CTD |
PMID:30802432 PMID:31606474 |
|
NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,541
|
|
G |
CDH2 |
cadherin 2 |
multiple interactions |
EXP |
fisetin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of CDH2 protein] |
CTD |
PMID:31606474 |
|
NCBI chr18:27,932,878...28,177,130
Ensembl chr18:27,932,879...28,177,946 Ensembl chr18:27,932,879...28,177,946
|
|
G |
CDK1 |
cyclin dependent kinase 1 |
decreases expression |
EXP |
fisetin results in decreased expression of CDK1 protein |
CTD |
PMID:28181380 |
|
NCBI chr10:60,778,331...60,794,852
Ensembl chr10:60,778,331...60,794,852
|
|
G |
CDK2 |
cyclin dependent kinase 2 |
decreases expression |
EXP |
fisetin results in decreased expression of CDK2 protein |
CTD |
PMID:28181380 |
|
NCBI chr12:55,966,830...55,972,789
Ensembl chr12:55,966,781...55,972,789
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
multiple interactions increases expression |
EXP |
[Cisplatin co-treated with fisetin] results in increased expression of CDKN1A protein fisetin results in increased expression of CDKN1A protein |
CTD |
PMID:21216935 |
|
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,339 Ensembl chr 6:36,676,460...36,687,339
|
|
G |
CHEK1 |
checkpoint kinase 1 |
increases expression |
EXP |
fisetin results in increased expression of CHEK1 protein |
CTD |
PMID:28181380 |
|
NCBI chr11:125,624,910...125,676,255
Ensembl chr11:125,625,665...125,676,255
|
|
G |
CHEK2 |
checkpoint kinase 2 |
increases expression |
EXP |
fisetin results in increased expression of CHEK2 protein |
CTD |
PMID:28181380 |
|
NCBI chr22:28,687,743...28,741,866
Ensembl chr22:28,687,743...28,742,422
|
|
G |
COMT |
catechol-O-methyltransferase |
multiple interactions |
EXP |
[fisetin co-treated with COMT protein] results in decreased activity of DNMT1 protein |
CTD |
PMID:16037419 |
|
NCBI chr22:19,941,772...19,969,975
Ensembl chr22:19,941,733...19,969,975 Ensembl chr22:19,941,733...19,969,975 Ensembl chr22:19,941,733...19,969,975
|
|
G |
CPLX2 |
complexin 2 |
multiple interactions |
ISO |
fisetin inhibits the reaction [methylmercuric chloride results in decreased expression of CPLX2 mRNA] |
CTD |
PMID:30890323 |
|
NCBI chr 5:175,796,533...175,884,021
Ensembl chr 5:175,796,310...175,884,021
|
|
G |
CREB1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
fisetin inhibits the reaction [Lead results in decreased phosphorylation of CREB1 protein] |
CTD |
PMID:31539617 |
|
NCBI chr 2:207,529,943...207,605,988
Ensembl chr 2:207,529,737...207,605,988
|
|
G |
CTNNB1 |
catenin beta 1 |
decreases expression multiple interactions |
EXP |
fisetin results in decreased expression of CTNNB1 protein fisetin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of CTNNB1 protein] |
CTD |
PMID:30802432 PMID:31606474 |
|
NCBI chr 3:41,199,422...41,240,445
Ensembl chr 3:41,194,741...41,260,096
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions |
EXP |
fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of CXCL8 mRNA]; fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased secretion of CXCL8 protein]; fisetin inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL8 protein]; fisetin inhibits the reaction [Silicon Dioxide results in increased expression of CXCL8 mRNA] |
CTD |
PMID:17884996 PMID:18958421 PMID:22931364 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,541...73,743,716
|
|
G |
CYBB |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
fisetin inhibits the reaction [Cisplatin results in increased expression of CYBB mRNA] |
CTD |
PMID:25184746 |
|
NCBI chr X:37,780,059...37,813,461
Ensembl chr X:37,780,059...37,813,461 Ensembl chr X:37,780,059...37,813,461
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
increases expression |
EXP |
fisetin results in increased expression of CYP1A1 mRNA |
CTD |
PMID:29584932 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP7A1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions |
ISO |
fisetin inhibits the reaction [Dietary Fats results in increased expression of CYP7A1 mRNA] |
CTD |
PMID:23524313 |
|
NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
multiple interactions increases expression |
EXP |
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [fisetin results in increased expression of DDIT3 protein] |
CTD |
PMID:28181380 |
|
NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
|
|
G |
DDN |
dendrin |
multiple interactions |
ISO |
fisetin inhibits the reaction [methylmercuric chloride results in decreased expression of DDN mRNA] |
CTD |
PMID:30890323 |
|
NCBI chr12:48,995,149...49,001,773
Ensembl chr12:48,995,149...48,999,375
|
|
G |
DIO2 |
iodothyronine deiodinase 2 |
increases activity |
EXP |
fisetin results in increased activity of DIO2 protein |
CTD |
PMID:17327447 |
|
NCBI chr14:80,197,526...80,231,057
Ensembl chr14:80,197,527...80,387,757 Ensembl chr14:80,197,527...80,387,757
|
|
G |
DLG4 |
discs large MAGUK scaffold protein 4 |
multiple interactions |
ISO |
fisetin inhibits the reaction [Lead results in decreased expression of DLG4 protein] |
CTD |
PMID:31539617 |
|
NCBI chr17:7,187,187...7,220,050
Ensembl chr17:7,189,890...7,219,841 Ensembl chr17:7,189,890...7,219,841 Ensembl chr17:7,189,890...7,219,841
|
|
G |
DNMT1 |
DNA methyltransferase 1 |
multiple interactions |
EXP |
[fisetin co-treated with COMT protein] results in decreased activity of DNMT1 protein |
CTD |
PMID:16037419 |
|
NCBI chr19:10,133,346...10,194,953
Ensembl chr19:10,133,345...10,231,286 Ensembl chr19:10,133,345...10,231,286
|
|
G |
EGFR |
epidermal growth factor receptor |
multiple interactions |
EXP |
fisetin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of EGFR protein modified form] |
CTD |
PMID:31606474 |
|
NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628
|
|
G |
EIF2AK3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
[fisetin co-treated with 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid] results in decreased expression of EIF2AK3 protein |
CTD |
PMID:28181380 |
|
NCBI chr 2:88,556,741...88,627,464
Ensembl chr 2:88,556,741...88,627,464
|
|
G |
ENDOG |
endonuclease G |
increases localization |
EXP |
fisetin results in increased localization of ENDOG protein |
CTD |
PMID:28181380 |
|
NCBI chr 9:128,818,402...128,822,676
Ensembl chr 9:128,818,500...128,822,676
|
|
G |
EP300 |
E1A binding protein p300 |
multiple interactions |
EXP |
fisetin promotes the reaction [Oxygen deficiency promotes the reaction [HIF1A protein binds to EP300 protein]] |
CTD |
PMID:20153296 |
|
NCBI chr22:41,092,592...41,180,077
Ensembl chr22:41,092,592...41,180,077
|
|
G |
ERBB2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
EXP |
fisetin results in decreased phosphorylation of and results in increased degradation of ERBB2 protein |
CTD |
PMID:30431692 |
|
NCBI chr17:39,688,094...39,728,660
Ensembl chr17:39,687,914...39,730,426
|
|
G |
ERBB3 |
erb-b2 receptor tyrosine kinase 3 |
decreases expression |
EXP |
fisetin results in decreased expression of ERBB3 protein |
CTD |
PMID:30431692 |
|
NCBI chr12:56,080,108...56,103,505
Ensembl chr12:56,076,799...56,103,505
|
|
G |
EXOC8 |
exocyst complex component 8 |
multiple interactions |
ISO |
fisetin inhibits the reaction [methylmercuric chloride results in decreased expression of EXOC8 mRNA] |
CTD |
PMID:30890323 |
|
NCBI chr 1:231,332,753...231,337,852
Ensembl chr 1:231,332,753...231,337,852
|
|
G |
FASLG |
Fas ligand |
multiple interactions increases expression |
EXP |
[Cisplatin co-treated with fisetin] results in increased expression of FASLG protein fisetin results in increased expression of FASLG protein |
CTD |
PMID:21216935 |
|
NCBI chr 1:172,659,103...172,666,876
Ensembl chr 1:172,659,103...172,666,876
|
|
G |
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
fisetin results in increased expression of and affects the localization of FOS protein |
CTD |
PMID:31044527 |
|
NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230
|
|
G |
GDNF |
glial cell derived neurotrophic factor |
multiple interactions |
ISO |
fisetin inhibits the reaction [methylmercuric chloride results in decreased expression of GDNF protein] |
CTD |
PMID:30890323 |
|
NCBI chr 5:37,812,677...37,840,044
Ensembl chr 5:37,812,677...37,840,041
|
|
G |
GFAP |
glial fibrillary acidic protein |
multiple interactions |
ISO |
fisetin inhibits the reaction [methylmercuric chloride results in increased expression of GFAP protein] |
CTD |
PMID:30890323 |
|
NCBI chr17:44,903,159...44,915,552
Ensembl chr17:44,903,159...44,916,937
|
|
G |
GSK3B |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
fisetin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of GSK3B protein modified form] |
CTD |
PMID:31606474 |
|
NCBI chr 3:119,821,321...120,095,823
Ensembl chr 3:119,821,323...120,094,417 Ensembl chr 3:119,821,323...120,094,417 Ensembl chr 3:119,821,323...120,094,417
|
|
G |
GSR |
glutathione-disulfide reductase |
multiple interactions |
ISO |
fisetin inhibits the reaction [Cisplatin results in decreased activity of GSR protein] |
CTD |
PMID:25184746 |
|
NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases expression increases activity |
ISO EXP |
cobaltous chloride promotes the reaction [fisetin results in increased activity of HIF1A protein]; fisetin promotes the reaction [cobaltous chloride results in increased activity of HIF1A protein]; fisetin results in increased expression of and affects the localization of HIF1A protein fisetin promotes the reaction [Oxygen deficiency promotes the reaction [HIF1A protein binds to EP300 protein]]; fisetin promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein] fisetin results in increased expression of HIF1A mRNA |
CTD |
PMID:20153296 PMID:25428606 |
|
NCBI chr14:61,695,513...61,748,259
Ensembl chr14:61,695,513...61,748,259
|
|
G |
HMOX1 |
heme oxygenase 1 |
increases expression multiple interactions |
EXP ISO |
fisetin results in increased expression of HMOX1 protein fisetin results in increased expression of HMOX1 mRNA; fisetin results in increased expression of HMOX1 protein Cycloheximide inhibits the reaction [fisetin results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [fisetin results in increased expression of HMOX1 protein]; HMOX1 protein promotes the reaction [fisetin results in decreased expression of MMP2 protein]; HMOX1 protein promotes the reaction [fisetin results in decreased expression of MMP9 protein]; NFE2L2 protein promotes the reaction [fisetin results in increased expression of HMOX1 protein] |
CTD |
PMID:16799064 PMID:30076913 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,207 Ensembl chr22:35,380,361...35,394,207
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions increases expression |
EXP |
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [fisetin results in increased expression of HSPA5 protein] |
CTD |
PMID:28181380 |
|
NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,343
|
|
G |
IL13 |
interleukin 13 |
multiple interactions |
EXP |
fisetin inhibits the reaction [[Calcimycin co-treated with phorbol-12-myristate] results in increased expression of IL13 protein]; fisetin inhibits the reaction [Calcimycin results in increased expression of IL13 mRNA] |
CTD |
PMID:12789233 |
|
NCBI chr 5:132,656,522...132,661,110
Ensembl chr 5:132,656,263...132,661,110
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
EXP |
fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL1B mRNA]; fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased secretion of IL1B protein] |
CTD |
PMID:18958421 |
|
NCBI chr 2:112,829,751...112,836,843
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL4 |
interleukin 4 |
multiple interactions decreases expression |
EXP |
fisetin inhibits the reaction [[Calcimycin co-treated with phorbol-12-myristate] results in increased expression of IL4 protein]; fisetin inhibits the reaction [Calcimycin results in increased expression of IL4 mRNA] fisetin results in decreased expression of IL4 protein |
CTD |
PMID:12789233 PMID:16343431 |
|
NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678
|
|
G |
IL5 |
interleukin 5 |
multiple interactions |
EXP |
fisetin inhibits the reaction [[Calcimycin co-treated with phorbol-12-myristate] results in increased expression of IL5 protein]; fisetin inhibits the reaction [Calcimycin results in increased expression of IL5 mRNA] |
CTD |
PMID:12789233 |
|
NCBI chr 5:132,539,194...132,556,864
Ensembl chr 5:132,541,445...132,556,838
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
EXP ISO |
fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL6 mRNA]; fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased secretion of IL6 protein]; fisetin inhibits the reaction [Silicon Dioxide results in increased expression of IL6 mRNA] fisetin inhibits the reaction [Lead results in increased expression of IL6 protein] |
CTD |
PMID:18958421 PMID:22931364 PMID:31539617 |
|
NCBI chr 7:22,725,889...22,732,002
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
fisetin results in increased phosphorylation of and affects the localization of JUN protein |
CTD |
PMID:31044527 |
|
NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,780,791...58,784,047 Ensembl chr 1:58,780,791...58,784,047
|
|
G |
KLK3 |
kallikrein related peptidase 3 |
multiple interactions decreases expression |
EXP |
fisetin inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 protein]; fisetin results in decreased expression of and results in decreased secretion of KLK3 protein fisetin results in decreased expression of KLK3 mRNA |
CTD |
PMID:18922931 |
|
NCBI chr19:50,854,915...50,860,764
Ensembl chr19:50,854,915...50,860,764
|
|
G |
LATS2 |
large tumor suppressor kinase 2 |
increases phosphorylation |
EXP |
fisetin results in increased phosphorylation of LATS2 protein |
CTD |
PMID:31044527 |
|
NCBI chr13:20,973,036...21,061,586
Ensembl chr13:20,973,036...21,061,586
|
|
G |
LIN7A |
lin-7 homolog A, crumbs cell polarity complex component |
multiple interactions |
ISO |
fisetin inhibits the reaction [methylmercuric chloride results in decreased expression of LIN7A mRNA] |
CTD |
PMID:30890323 |
|
NCBI chr12:80,792,520...80,937,934
Ensembl chr12:80,792,520...80,937,925
|
|
G |
MAP3K20 |
mitogen-activated protein kinase kinase kinase 20 |
increases expression |
EXP |
fisetin results in increased expression of MAP3K20 protein |
CTD |
PMID:31044527 |
|
NCBI chr 2:173,075,435...173,268,015
Ensembl chr 2:173,075,435...173,268,015
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
increases phosphorylation multiple interactions |
EXP ISO |
fisetin results in increased phosphorylation of MAPK1 protein fisetin inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:21964635 PMID:25428606 PMID:31044527 PMID:31606474 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,754,500...21,867,680 Ensembl chr22:21,754,500...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
increases phosphorylation multiple interactions |
EXP ISO |
fisetin results in increased phosphorylation of MAPK3 protein fisetin inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:21964635 PMID:25428606 PMID:31044527 PMID:31606474 |
|
NCBI chr16:30,114,105...30,123,309
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MAPT |
microtubule associated protein tau |
multiple interactions |
ISO |
fisetin inhibits the reaction [Lead results in increased phosphorylation of MAPT protein] |
CTD |
PMID:31539617 |
|
NCBI chr17:45,894,538...46,028,334
Ensembl chr17:45,894,551...46,028,334 Ensembl chr17:45,894,551...46,028,334
|
|
G |
MME |
membrane metalloendopeptidase |
multiple interactions |
ISO |
fisetin inhibits the reaction [Lead results in decreased expression of MME protein] |
CTD |
PMID:31539617 |
|
NCBI chr 3:155,024,202...155,183,729
Ensembl chr 3:155,024,124...155,183,704 Ensembl chr 3:155,024,124...155,183,704
|
|
G |
MMP2 |
matrix metallopeptidase 2 |
multiple interactions decreases expression |
ISO EXP |
HMOX1 protein promotes the reaction [fisetin results in decreased expression of MMP2 protein]; NFE2L2 protein promotes the reaction [fisetin results in decreased expression of MMP2 protein]; tin protoporphyrin IX inhibits the reaction [fisetin results in decreased expression of MMP2 mRNA]; tin protoporphyrin IX inhibits the reaction [fisetin results in decreased expression of MMP2 protein]; zinc protoporphyrin inhibits the reaction [fisetin results in decreased expression of MMP2 mRNA]; zinc protoporphyrin inhibits the reaction [fisetin results in decreased expression of MMP2 protein] fisetin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of and results in increased activity of MMP2 protein] fisetin results in decreased expression of MMP2 mRNA; fisetin results in decreased expression of MMP2 protein |
CTD |
PMID:30076913 PMID:31606474 |
|
NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression |
EXP ISO |
fisetin inhibits the reaction [Silicon Dioxide results in increased expression of MMP9 mRNA]; fisetin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of and results in increased activity of MMP9 protein] fisetin results in decreased expression of MMP9 mRNA; fisetin results in decreased expression of MMP9 protein HMOX1 protein promotes the reaction [fisetin results in decreased expression of MMP9 protein]; NFE2L2 protein promotes the reaction [fisetin results in decreased expression of MMP9 protein]; tin protoporphyrin IX inhibits the reaction [fisetin results in decreased expression of MMP9 mRNA]; tin protoporphyrin IX inhibits the reaction [fisetin results in decreased expression of MMP9 protein]; zinc protoporphyrin inhibits the reaction [fisetin results in decreased expression of MMP9 mRNA]; zinc protoporphyrin inhibits the reaction [fisetin results in decreased expression of MMP9 protein] |
CTD |
PMID:22931364 PMID:30076913 PMID:31606474 |
|
NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
|
|
G |
MPO |
myeloperoxidase |
multiple interactions |
ISO |
fisetin inhibits the reaction [Cisplatin results in increased activity of MPO protein] |
CTD |
PMID:25184746 |
|
NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
|
|
G |
MYD88 |
MYD88 innate immune signal transduction adaptor |
multiple interactions |
ISO |
fisetin inhibits the reaction [Lead results in increased expression of MYD88 protein] |
CTD |
PMID:31539617 |
|
NCBI chr 3:38,138,661...38,143,022
Ensembl chr 3:38,138,478...38,143,022
|
|
G |
NFATC2 |
nuclear factor of activated T cells 2 |
multiple interactions |
EXP |
fisetin inhibits the reaction [Calcimycin results in increased activity of NFATC2 protein] |
CTD |
PMID:12789233 |
|
NCBI chr20:51,386,963...51,562,857
Ensembl chr20:51,386,957...51,562,831
|
|
G |
NFE2L2 |
nuclear factor, erythroid 2 like 2 |
increases expression multiple interactions |
EXP ISO |
fisetin results in increased expression of NFE2L2 protein NFE2L2 protein promotes the reaction [fisetin results in decreased expression of MMP2 protein]; NFE2L2 protein promotes the reaction [fisetin results in decreased expression of MMP9 protein]; NFE2L2 protein promotes the reaction [fisetin results in increased expression of HMOX1 protein] |
CTD |
PMID:16799064 PMID:30076913 |
|
NCBI chr 2:177,230,303...177,265,131
Ensembl chr 2:177,227,595...177,392,697
|
|
G |
NFKB1 |
nuclear factor kappa B subunit 1 |
decreases expression |
EXP |
fisetin results in decreased expression of NFKB1 protein |
CTD |
PMID:30802432 |
|
NCBI chr 4:102,501,266...102,617,302
Ensembl chr 4:102,501,331...102,617,302
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
multiple interactions |
ISO |
fisetin inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:25184746 |
|
NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,511...35,404,749 Ensembl chr14:35,401,511...35,404,749
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
fisetin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] fisetin inhibits the reaction [Cisplatin results in increased expression of NOS2 protein] |
CTD |
PMID:17177504 PMID:25184746 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NOX4 |
NADPH oxidase 4 |
multiple interactions |
ISO |
fisetin inhibits the reaction [Cisplatin results in increased expression of NOX4 mRNA] |
CTD |
PMID:25184746 |
|
NCBI chr11:89,324,353...89,589,557
Ensembl chr11:89,324,353...89,498,187
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
fisetin inhibits the reaction [Cisplatin results in decreased activity of NQO1 protein] |
CTD |
PMID:25184746 |
|
NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
increases expression |
EXP |
fisetin results in increased expression of NR1I2 mRNA |
CTD |
PMID:29933105 |
|
NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,485
|
|
G |
NRGN |
neurogranin |
multiple interactions |
ISO |
fisetin inhibits the reaction [methylmercuric chloride results in decreased expression of NRGN mRNA] |
CTD |
PMID:30890323 |
|
NCBI chr11:124,739,942...124,747,210
Ensembl chr11:124,739,942...124,747,210
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
decreases activity |
EXP |
fisetin results in decreased activity of PARP1 protein |
CTD |
PMID:17884996 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,691...226,408,093 Ensembl chr 1:226,360,691...226,408,093
|
|
G |
PROM1 |
prominin 1 |
decreases expression |
EXP |
fisetin results in decreased expression of PROM1 protein |
CTD |
PMID:30802432 |
|
NCBI chr 4:15,968,226...16,084,059
Ensembl chr 4:15,963,076...16,084,378
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] affects the localization of and results in increased activity of RELA protein] fisetin inhibits the reaction [Lead affects the localization of RELA protein] fisetin inhibits the reaction [Cisplatin affects the localization of and results in increased activity of RELA protein] |
CTD |
PMID:18958421 PMID:25184746 PMID:31539617 |
|
NCBI chr11:65,653,601...65,662,946
Ensembl chr11:65,653,597...65,663,090
|
|
G |
SIRT1 |
sirtuin 1 |
multiple interactions |
ISO |
fisetin inhibits the reaction [Lead results in decreased expression of SIRT1 protein] |
CTD |
PMID:31539617 |
|
NCBI chr10:67,884,656...67,918,390
Ensembl chr10:67,884,656...67,918,390
|
|
G |
SLC16A1 |
solute carrier family 16 member 1 |
multiple interactions |
ISO |
[fisetin results in decreased activity of SLC16A1 protein] which results in decreased uptake of Sodium Oxybate |
CTD |
PMID:17108059 |
|
NCBI chr 1:112,911,847...112,956,196
Ensembl chr 1:112,911,847...112,957,013
|
|
G |
SLC2A3 |
solute carrier family 2 member 3 |
multiple interactions |
EXP |
[fisetin co-treated with Oxygen deficiency] results in decreased expression of SLC2A3 mRNA |
CTD |
PMID:20153296 |
|
NCBI chr12:7,919,230...7,936,187
Ensembl chr12:7,919,230...7,936,187
|
|
G |
SLC2A4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
fisetin inhibits the reaction [INS1 protein affects the localization of SLC2A4 protein] |
CTD |
PMID:18591783 |
|
NCBI chr17:7,281,718...7,288,257
Ensembl chr17:7,281,718...7,288,257
|
|
G |
SNAP25 |
synaptosome associated protein 25 |
multiple interactions |
ISO |
fisetin inhibits the reaction [Lead results in decreased expression of SNAP25 protein] |
CTD |
PMID:31539617 |
|
NCBI chr20:10,218,830...10,307,420
Ensembl chr20:10,218,830...10,307,418
|
|
G |
SREBF2 |
sterol regulatory element binding transcription factor 2 |
increases expression |
EXP |
fisetin results in increased expression of SREBF2 protein alternative form |
CTD |
PMID:23524313 |
|
NCBI chr22:41,833,105...41,907,308
Ensembl chr22:41,833,079...41,907,307
|
|
G |
STAT3 |
signal transducer and activator of transcription 3 |
multiple interactions decreases expression |
EXP |
fisetin inhibits the reaction [Oxygen deficiency results in increased phosphorylation of STAT3 protein] fisetin results in decreased expression of STAT3 protein |
CTD |
PMID:20153296 PMID:30802432 |
|
NCBI chr17:42,313,324...42,388,502
Ensembl chr17:42,313,324...42,388,482 Ensembl chr17:42,313,324...42,388,482 Ensembl chr17:42,313,324...42,388,482
|
|
G |
STX1A |
syntaxin 1A |
multiple interactions |
ISO |
fisetin inhibits the reaction [methylmercuric chloride results in decreased expression of STX1A mRNA] |
CTD |
PMID:30890323 |
|
NCBI chr 7:73,699,210...73,719,673
Ensembl chr 7:73,699,206...73,719,672
|
|
G |
TLR4 |
toll like receptor 4 |
multiple interactions |
ISO |
fisetin inhibits the reaction [Lead results in increased expression of TLR4 protein] |
CTD |
PMID:31539617 |
|
NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP ISO |
fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of TNF mRNA]; fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased secretion of TNF protein] fisetin inhibits the reaction [Lead results in increased expression of TNF protein] fisetin inhibits the reaction [Cisplatin results in increased expression of TNF protein] |
CTD |
PMID:18958421 PMID:25184746 PMID:31539617 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions affects localization increases expression |
EXP ISO |
[Cisplatin co-treated with fisetin] affects the localization of TP53 protein; [Cisplatin co-treated with fisetin] results in increased expression of TP53 protein; [Cisplatin co-treated with fisetin] results in increased phosphorylation of TP53 protein; fisetin inhibits the reaction [Silicon Dioxide results in increased expression of TP53 mRNA]; SB 203580 inhibits the reaction [[Cisplatin co-treated with fisetin] results in increased phosphorylation of TP53 protein] fisetin inhibits the reaction [Cisplatin results in increased expression of TP53 protein] fisetin affects the localization of TP53 protein fisetin results in increased expression of TP53 protein |
CTD |
PMID:21216935 PMID:22931364 PMID:25184746 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538 Ensembl chr17:7,661,779...7,687,538
|
|
G |
UGT1A1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation |
EXP |
UGT1A1 protein results in increased glucuronidation of fisetin |
CTD |
PMID:14557274 |
|
NCBI chr 2:233,760,270...233,773,300
Ensembl chr 2:233,760,270...233,773,300 Ensembl chr 2:233,760,270...233,773,300
|
|
G |
UGT1A10 |
UDP glucuronosyltransferase family 1 member A10 |
increases glucuronidation |
EXP |
UGT1A10 protein results in increased glucuronidation of fisetin |
CTD |
PMID:14557274 |
|
NCBI chr 2:233,636,477...233,773,305
Ensembl chr 2:233,636,454...233,773,305
|
|
G |
UGT1A7 |
UDP glucuronosyltransferase family 1 member A7 |
increases glucuronidation |
EXP |
UGT1A7 protein results in increased glucuronidation of fisetin |
CTD |
PMID:14557274 |
|
NCBI chr 2:233,681,901...233,773,300
Ensembl chr 2:233,681,938...233,773,299
|
|
G |
UGT1A8 |
UDP glucuronosyltransferase family 1 member A8 |
increases glucuronidation |
EXP |
UGT1A8 protein results in increased glucuronidation of fisetin |
CTD |
PMID:14557274 |
|
NCBI chr 2:233,617,633...233,773,300
Ensembl chr 2:233,617,645...233,773,310
|
|
G |
UGT1A9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation |
EXP |
UGT1A9 protein results in increased glucuronidation of fisetin |
CTD |
PMID:14557274 |
|
NCBI chr 2:233,671,898...233,773,300
Ensembl chr 2:233,671,898...233,773,300
|
|
G |
VEGFA |
vascular endothelial growth factor A |
multiple interactions |
EXP |
fisetin inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA mRNA]; fisetin inhibits the reaction [Oxygen deficiency results in increased secretion of VEGFA protein]; fisetin promotes the reaction [Oxygen deficiency results in increased expression of and results in increased localization of VEGFA protein] |
CTD |
PMID:20153296 |
|
NCBI chr 6:43,770,209...43,786,487
Ensembl chr 6:43,770,184...43,786,487
|
|
G |
VIM |
vimentin |
decreases expression multiple interactions |
EXP |
fisetin results in decreased expression of VIM protein fisetin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of VIM protein] |
CTD |
PMID:30802432 PMID:31606474 |
|
NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593
|
|
G |
YAP1 |
Yes1 associated transcriptional regulator |
multiple interactions |
EXP |
fisetin results in increased phosphorylation of and affects the localization of YAP1 protein |
CTD |
PMID:31044527 |
|
NCBI chr11:102,109,957...102,233,424
Ensembl chr11:102,110,447...102,233,424
|
|
|
G |
FASN |
fatty acid synthase |
multiple interactions |
ISO |
herbacetin inhibits the reaction [Dietary Fats results in increased activity of FASN protein] |
CTD |
PMID:29653099 |
|
NCBI chr17:82,078,338...82,098,303
Ensembl chr17:82,078,338...82,098,294
|
|
G |
G6PD |
glucose-6-phosphate dehydrogenase |
multiple interactions |
ISO |
herbacetin inhibits the reaction [Dietary Fats results in increased activity of G6PD protein] |
CTD |
PMID:29653099 |
|
NCBI chr X:154,531,390...154,547,569
Ensembl chr X:154,531,391...154,547,572
|
|
G |
GPT |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
herbacetin inhibits the reaction [Dietary Fats results in increased activity of GPT protein] |
CTD |
PMID:29653099 |
|
NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174
|
|
G |
SREBF1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
herbacetin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA] |
CTD |
PMID:29653099 |
|
NCBI chr17:17,811,334...17,837,017
Ensembl chr17:17,810,399...17,837,011
|
|
G |
SREBF2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions |
ISO |
herbacetin inhibits the reaction [Dietary Fats results in increased expression of SREBF2 mRNA] |
CTD |
PMID:29653099 |
|
NCBI chr22:41,833,105...41,907,308
Ensembl chr22:41,833,079...41,907,307
|
|
|
G |
ADIPOQ |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of ADIPOQ mRNA]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of ADIPOQ protein] |
CTD |
PMID:30055130 |
|
NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463
|
|
G |
CEBPA |
CCAAT enhancer binding protein alpha |
multiple interactions |
ISO |
hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of CEBPA mRNA] |
CTD |
PMID:30055130 |
|
NCBI chr19:33,299,934...33,302,564
Ensembl chr19:33,299,934...33,302,534
|
|
G |
INS |
insulin |
multiple interactions |
ISO |
hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of ADIPOQ mRNA]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of ADIPOQ protein]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of PPARG mRNA]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of PPARG protein] |
CTD |
PMID:30055130 |
|
NCBI chr11:2,159,779...2,161,209
Ensembl chr11:2,159,779...2,161,341 Ensembl chr11:2,159,779...2,161,341
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions |
ISO |
hispidulin inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:22759588 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,754,500...21,867,680 Ensembl chr22:21,754,500...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions |
ISO |
hispidulin inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:22759588 |
|
NCBI chr16:30,114,105...30,123,309
Ensembl chr16:30,114,105...30,123,506
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions |
ISO |
hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of PPARG mRNA]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of PPARG protein] |
CTD |
PMID:30055130 |
|
NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
|
|
G |
SLCO1B1 |
solute carrier organic anion transporter family member 1B1 |
multiple interactions decreases activity |
EXP |
[hispidulin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Fluvastatin |
CTD |
PMID:32259555 |
|
NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
|
|
G |
SYN1 |
synapsin I |
affects response to substance |
ISO |
SYN1 protein affects the susceptibility to hispidulin |
CTD |
PMID:22759588 |
|
NCBI chr X:47,571,901...47,619,857
Ensembl chr X:47,571,901...47,619,857
|
|
|
G |
ACTA2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
homoorientin inhibits the reaction [Ethanol results in increased expression of ACTA2 protein] |
CTD |
PMID:22446813 |
|
NCBI chr10:88,935,074...88,991,397
Ensembl chr10:88,935,074...88,991,339
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation multiple interactions |
EXP |
homoorientin results in decreased phosphorylation of AKT1 protein homoorientin promotes the reaction [Zinc Oxide analog results in decreased phosphorylation of AKT1 protein]; Zinc Oxide analog promotes the reaction [homoorientin results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:24374571 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions |
ISO |
homoorientin inhibits the reaction [Ethanol results in increased expression of BCL2 mRNA] |
CTD |
PMID:22446813 |
|
NCBI chr18:63,123,346...63,320,280
Ensembl chr18:63,123,346...63,320,128
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
ISO |
homoorientin inhibits the reaction [Ethanol results in increased expression of IL6 protein] |
CTD |
PMID:22446813 |
|
NCBI chr 7:22,725,889...22,732,002
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP |
homoorientin promotes the reaction [Zinc Oxide analog results in decreased phosphorylation of MAPK1 protein]; Zinc Oxide analog promotes the reaction [homoorientin results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:24374571 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,754,500...21,867,680 Ensembl chr22:21,754,500...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP |
homoorientin promotes the reaction [Zinc Oxide analog results in decreased phosphorylation of MAPK3 protein]; Zinc Oxide analog promotes the reaction [homoorientin results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:24374571 |
|
NCBI chr16:30,114,105...30,123,309
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MPO |
myeloperoxidase |
multiple interactions |
ISO |
homoorientin inhibits the reaction [Ethanol results in increased activity of MPO protein] |
CTD |
PMID:22446813 |
|
NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
multiple interactions |
ISO |
homoorientin inhibits the reaction [Ethanol results in increased expression of TGFB1 protein] |
CTD |
PMID:22446813 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
ISO |
homoorientin inhibits the reaction [Ethanol results in increased expression of TNF protein] |
CTD |
PMID:22446813 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
increases transport increases expression |
EXP |
ABCB1 protein results in increased transport of 3-methylquercetin 3-methylquercetin results in increased expression of ABCB1 mRNA |
CTD |
PMID:15969930 PMID:26238175 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323 Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ABCC1 |
ATP binding cassette subfamily C member 1 |
decreases activity |
EXP |
3-methylquercetin results in decreased activity of ABCC1 protein |
CTD |
PMID:15670588 |
|
NCBI chr16:15,949,616...16,143,062
Ensembl chr16:15,949,577...16,143,074 Ensembl chr16:15,949,577...16,143,074
|
|
G |
ACTA2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP ISO |
3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] 3-methylquercetin inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:27151496 |
|
NCBI chr10:88,935,074...88,991,397
Ensembl chr10:88,935,074...88,991,339
|
|
G |
AGT |
angiotensinogen |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [AGT protein results in increased expression of NCF1 protein] |
CTD |
PMID:17374653 |
|
NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,702,523...230,714,122
|
|
G |
AHR |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
3-methylquercetin inhibits the reaction [Benzo(a)pyrene results in increased activity of AHR protein] |
CTD |
PMID:19794518 |
|
NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation multiple interactions |
ISO |
3-methylquercetin results in decreased phosphorylation of AKT1 protein 3-methylquercetin affects the reaction [Hydrogen Peroxide results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:12826665 PMID:19222219 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
decreases expression |
EXP |
3-methylquercetin results in decreased expression of BCL2 mRNA; 3-methylquercetin results in decreased expression of BCL2 protein |
CTD |
PMID:22992727 |
|
NCBI chr18:63,123,346...63,320,280
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BCL2L1 |
BCL2 like 1 |
decreases expression |
EXP |
3-methylquercetin results in decreased expression of BCL2L1 mRNA; 3-methylquercetin results in decreased expression of BCL2L1 protein |
CTD |
PMID:22992727 |
|
NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
|
|
G |
CASP3 |
caspase 3 |
decreases expression multiple interactions increases activity |
EXP ISO |
3-methylquercetin results in decreased expression of CASP3 protein 3-methylquercetin inhibits the reaction [Hydrogen Peroxide results in increased activity of CASP3 protein] 3-methylquercetin results in increased activity of CASP3 protein |
CTD |
PMID:12826665 PMID:19222219 PMID:22992727 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
|
|
G |
CASP9 |
caspase 9 |
decreases expression |
EXP |
3-methylquercetin results in decreased expression of CASP9 protein |
CTD |
PMID:22992727 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Hydrogen Peroxide results in decreased activity of CAT protein]; [quercetin 3-O-glucuronide co-treated with 3-methylquercetin co-treated with Quercetin] results in increased expression of CAT mRNA; [quercetin 3-O-glucuronide co-treated with 3-methylquercetin co-treated with Quercetin] results in increased expression of CAT protein |
CTD |
PMID:19222219 PMID:25716194 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCL3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[3-methylquercetin co-treated with Lipopolysaccharides] affects the expression of CCL3 mRNA |
CTD |
PMID:20579867 |
|
NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169
|
|
G |
CCND1 |
cyclin D1 |
decreases expression |
EXP |
3-methylquercetin results in decreased expression of CCND1 mRNA; 3-methylquercetin results in decreased expression of CCND1 protein |
CTD |
PMID:22992727 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474 Ensembl chr11:69,641,156...69,654,474
|
|
G |
COL1A1 |
collagen type I alpha 1 chain |
multiple interactions |
EXP ISO |
3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:27151496 |
|
NCBI chr17:50,184,096...50,201,649
Ensembl chr17:50,183,289...50,201,632 Ensembl chr17:50,183,289...50,201,632
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
multiple interactions |
EXP |
3-methylquercetin inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1A1 protein]; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin co-treated with ginkgolide A co-treated with ginkgolide B co-treated with ginkgolide C co-treated with ginkgolide J co-treated with bilobalide] affects the activity of CYP1A1 protein; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin co-treated with ginkgolide A co-treated with ginkgolide B co-treated with ginkgolide C co-treated with ginkgolide J co-treated with bilobalide] inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1A1 protein]; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin co-treated with ginkgolide A co-treated with ginkgolide B co-treated with ginkgolide C co-treated with ginkgolide J co-treated with bilobalide] inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin] affects the activity of CYP1A1 protein; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin] inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1A1 protein]; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin] inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] |
CTD |
PMID:21329749 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
decreases expression |
EXP |
3-methylquercetin results in decreased expression of CYP1B1 mRNA |
CTD |
PMID:19794518 |
|
NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
increases expression |
EXP |
3-methylquercetin results in increased expression of CYP3A4 mRNA |
CTD |
PMID:26238175 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
EDN1 |
endothelin 1 |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [EDN1 protein results in increased expression of NCF1 mRNA]; 3-methylquercetin inhibits the reaction [EDN1 protein results in increased expression of NCF1 protein] |
CTD |
PMID:18436224 |
|
NCBI chr 6:12,256,463...12,297,194
Ensembl chr 6:12,290,361...12,297,194
|
|
G |
ESR1 |
estrogen receptor 1 |
affects binding |
EXP |
3-methylquercetin binds to ESR1 protein |
CTD |
PMID:14706564 |
|
NCBI chr 6:151,654,148...152,129,619
Ensembl chr 6:151,656,691...152,129,619
|
|
G |
ESR2 |
estrogen receptor 2 |
affects binding |
EXP |
3-methylquercetin binds to ESR2 protein |
CTD |
PMID:14706564 |
|
NCBI chr14:64,226,707...64,338,631
Ensembl chr14:64,084,232...64,338,112
|
|
G |
GCLC |
glutamate-cysteine ligase catalytic subunit |
multiple interactions increases expression |
EXP ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein]; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein; dorsomorphin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein]; rottlerin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein] [quercetin 3-O-glucuronide co-treated with 3-methylquercetin co-treated with Quercetin] results in increased expression of GCLC mRNA; [quercetin 3-O-glucuronide co-treated with 3-methylquercetin co-treated with Quercetin] results in increased expression of GCLC protein 3-methylquercetin results in increased expression of GCLC mRNA; 3-methylquercetin results in increased expression of GCLC protein |
CTD |
PMID:24211276 PMID:25716194 |
|
NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970
|
|
G |
GPT |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Carbon Tetrachloride results in increased expression of GPT protein] |
CTD |
PMID:27151496 |
|
NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174
|
|
G |
HMOX1 |
heme oxygenase 1 |
multiple interactions increases expression |
EXP ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein]; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein; dorsomorphin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein]; rottlerin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein] [quercetin 3-O-glucuronide co-treated with 3-methylquercetin co-treated with Quercetin] results in increased expression of HMOX1 mRNA; [quercetin 3-O-glucuronide co-treated with 3-methylquercetin co-treated with Quercetin] results in increased expression of HMOX1 protein 3-methylquercetin results in increased expression of HMOX1 mRNA; 3-methylquercetin results in increased expression of HMOX1 protein 3-methylquercetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of HMOX1 mRNA]; [3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein |
CTD |
PMID:24211276 PMID:24337631 PMID:25716194 PMID:27151496 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,207 Ensembl chr22:35,380,361...35,394,207
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of IL1B protein] 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL1B protein]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; [3-methylquercetin co-treated with Lipopolysaccharides] affects the expression of IL1B mRNA |
CTD |
PMID:20579867 PMID:23774260 |
|
NCBI chr 2:112,829,751...112,836,843
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of IL6 protein] 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; [3-methylquercetin co-treated with Lipopolysaccharides] affects the expression of IL6 mRNA |
CTD |
PMID:20579867 PMID:23774260 |
|
NCBI chr 7:22,725,889...22,732,002
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:19222219 |
|
NCBI chr10:48,306,673...48,439,360
Ensembl chr10:48,306,639...48,439,360
|
|
G |
MIR155 |
microRNA 155 |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of MIR155 mRNA] |
CTD |
PMID:20579867 |
|
NCBI chr21:25,573,980...25,574,044
Ensembl chr21:25,573,980...25,574,044
|
|
G |
NCF1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [AGT protein results in increased expression of NCF1 protein]; 3-methylquercetin inhibits the reaction [EDN1 protein results in increased expression of NCF1 mRNA]; 3-methylquercetin inhibits the reaction [EDN1 protein results in increased expression of NCF1 protein] |
CTD |
PMID:17374653 PMID:18436224 |
|
NCBI chr 7:74,773,962...74,789,376
Ensembl chr 7:74,773,962...74,789,376
|
|
G |
NFE2L2 |
nuclear factor, erythroid 2 like 2 |
affects response to substance multiple interactions affects localization increases activity |
EXP ISO |
NFE2L2 protein affects the susceptibility to 3-methylquercetin 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein]; 3-methylquercetin affects the localization of and results in increased phosphorylation of and results in increased activity of NFE2L2 protein; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased abundance of Glutathione; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of SESN2 mRNA; dorsomorphin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein]; dorsomorphin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]]; NFE2L2 protein affects the reaction [3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]]; rottlerin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein]; rottlerin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein] 3-methylquercetin affects the localization of NFE2L2 protein [3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein; [3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein; NFE2L2 protein affects the reaction [3-methylquercetin results in decreased susceptibility to tert-Butylhydroperoxide] |
CTD |
PMID:24211276 PMID:27151496 |
|
NCBI chr 2:177,230,303...177,265,131
Ensembl chr 2:177,227,595...177,392,697
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:23774260 |
|
NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,511...35,404,749 Ensembl chr14:35,401,511...35,404,749
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [[Lipopolysaccharides results in increased expression of and results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of NOS2 protein]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; [3-methylquercetin co-treated with Lipopolysaccharides] affects the expression of NOS2 mRNA |
CTD |
PMID:16213685 PMID:18178435 PMID:18274639 PMID:20579867 PMID:23774260 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NOS3 |
nitric oxide synthase 3 |
multiple interactions |
EXP |
3-methylquercetin inhibits the reaction [Lipids results in decreased expression of NOS3] |
CTD |
PMID:16891912 |
|
NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
[3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA |
CTD |
PMID:24211276 |
|
NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
multiple interactions increases activity |
EXP ISO |
3-methylquercetin binds to and results in increased activity of NR1I2 protein 3-methylquercetin results in increased activity of NR1I2 protein |
CTD |
PMID:26238175 |
|
NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,485
|
|
G |
OLR1 |
oxidized low density lipoprotein receptor 1 |
multiple interactions |
EXP |
3-methylquercetin inhibits the reaction [Lipids results in increased expression of OLR1] |
CTD |
PMID:16891912 |
|
NCBI chr12:10,158,301...10,172,132
Ensembl chr12:10,158,301...10,172,138
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
increases cleavage |
EXP |
3-methylquercetin results in increased cleavage of PARP1 protein |
CTD |
PMID:22992727 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,691...226,408,093 Ensembl chr 1:226,360,691...226,408,093
|
|
G |
PECAM1 |
platelet and endothelial cell adhesion molecule 1 |
decreases expression |
EXP |
3-methylquercetin results in decreased expression of PECAM1 protein |
CTD |
PMID:22992727 |
|
NCBI chr17:64,319,415...64,413,844
Ensembl chr17:64,319,415...64,413,776
|
|
G |
PON1 |
paraoxonase 1 |
increases expression |
EXP |
3-methylquercetin results in increased expression of PON1 mRNA |
CTD |
PMID:20228421 |
|
NCBI chr 7:95,297,676...95,324,532
Ensembl chr 7:95,297,676...95,324,532
|
|
G |
PON2 |
paraoxonase 2 |
increases expression |
ISO |
3-methylquercetin results in increased expression of PON2 mRNA |
CTD |
PMID:19865538 |
|
NCBI chr 7:95,404,862...95,435,028
Ensembl chr 7:95,404,862...95,435,329
|
|
G |
PPARD |
peroxisome proliferator activated receptor delta |
increases activity |
EXP |
3-methylquercetin results in increased activity of PPARD protein |
CTD |
PMID:22992727 |
|
NCBI chr 6:35,342,558...35,428,180
Ensembl chr 6:35,342,558...35,428,191
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions increases expression |
EXP |
2-chloro-5-nitrobenzanilide inhibits the reaction [3-methylquercetin results in increased activity of PPARG protein]; 3-methylquercetin binds to and results in increased activity of PPARG protein 3-methylquercetin results in increased expression of PPARG protein |
CTD |
PMID:22992727 |
|
NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
|
|
G |
PRKCD |
protein kinase C delta |
increases phosphorylation |
EXP |
3-methylquercetin results in increased phosphorylation of PRKCD protein |
CTD |
PMID:24211276 |
|
NCBI chr 3:53,161,209...53,192,717
Ensembl chr 3:53,156,009...53,192,717
|
|
G |
PTGES |
prostaglandin E synthase |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGES mRNA] |
CTD |
PMID:21341175 |
|
NCBI chr 9:129,738,349...129,753,042
Ensembl chr 9:129,738,331...129,753,042
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions decreases activity |
ISO EXP |
3-methylquercetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 mRNA]; 3-methylquercetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 protein]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; 3-methylquercetin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein]; Acetylcysteine promotes the reaction [3-methylquercetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 protein]]; tin protoporphyrin IX inhibits the reaction [3-methylquercetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 protein]] 3-methylquercetin results in decreased activity of PTGS2 protein 3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein] |
CTD |
PMID:15292928 PMID:21341175 PMID:24337631 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,423
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Lipopolysaccharides affects the localization of and results in increased activity of RELA protein]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein] |
CTD |
PMID:18274639 PMID:20579867 PMID:23774260 |
|
NCBI chr11:65,653,601...65,662,946
Ensembl chr11:65,653,597...65,663,090
|
|
G |
SERPINE1 |
serpin family E member 1 |
multiple interactions |
EXP ISO |
3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 protein]; NFE2L2 protein affects the reaction [3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]] 3-methylquercetin inhibits the reaction [Carbon Tetrachloride results in increased expression of SERPINE1 protein]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 protein] |
CTD |
PMID:27151496 |
|
NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247 Ensembl chr 7:101,127,104...101,139,247
|
|
G |
SESN2 |
sestrin 2 |
multiple interactions |
EXP |
[3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of SESN2 mRNA |
CTD |
PMID:24211276 |
|
NCBI chr 1:28,259,452...28,282,491
Ensembl chr 1:28,259,518...28,282,491
|
|
G |
SMAD2 |
SMAD family member 2 |
multiple interactions |
EXP |
3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:27151496 |
|
NCBI chr18:47,808,957...47,931,188
Ensembl chr18:47,808,957...47,931,146
|
|
G |
SMAD3 |
SMAD family member 3 |
multiple interactions |
EXP |
3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]; NFE2L2 protein affects the reaction [3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]] |
CTD |
PMID:27151496 |
|
NCBI chr15:67,065,602...67,195,195
Ensembl chr15:67,063,763...67,195,169
|
|
G |
TFF1 |
trefoil factor 1 |
increases expression |
EXP |
3-methylquercetin results in increased expression of TFF1 mRNA |
CTD |
PMID:14706564 |
|
NCBI chr21:42,362,282...42,366,535
Ensembl chr21:42,362,282...42,366,535
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
multiple interactions |
EXP ISO |
3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 protein]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]; NFE2L2 protein affects the reaction [3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]]; NFE2L2 protein affects the reaction [3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]] |
CTD |
PMID:27151496 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of TNF protein] 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of TNF protein]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:20579867 PMID:23774260 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TYR |
tyrosinase |
increases expression |
ISO |
3-methylquercetin results in increased expression of TYR protein |
CTD |
PMID:24853321 |
|
NCBI chr11:89,177,565...89,295,759
Ensembl chr11:89,177,875...89,295,759
|
|
G |
TYRP1 |
tyrosinase related protein 1 |
increases expression |
ISO |
3-methylquercetin results in increased expression of TYRP1 protein |
CTD |
PMID:24853321 |
|
NCBI chr 9:12,693,375...12,710,285
Ensembl chr 9:12,685,439...12,710,285
|
|
|
G |
SLC2A1 |
solute carrier family 2 member 1 |
decreases expression |
EXP |
kaempferide results in decreased expression of SLC2A1 mRNA |
CTD |
PMID:21865046 |
|
NCBI chr 1:42,925,353...42,958,868
Ensembl chr 1:42,925,353...42,958,893 Ensembl chr 1:42,925,353...42,958,893
|
|
G |
VEGFA |
vascular endothelial growth factor A |
increases expression |
EXP |
kaempferide results in increased expression of VEGFA mRNA |
CTD |
PMID:21865046 |
|
NCBI chr 6:43,770,209...43,786,487
Ensembl chr 6:43,770,184...43,786,487
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
increases transport multiple interactions |
EXP |
ABCB1 protein results in increased transport of kaempferol kaempferol inhibits the reaction [[ABCB1 protein results in decreased susceptibility to Doxorubicin] promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of ABCB1 mRNA]]; kaempferol inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir] |
CTD |
PMID:15266218 PMID:15969930 PMID:20438634 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323 Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ABCC1 |
ATP binding cassette subfamily C member 1 |
decreases activity increases activity multiple interactions affects activity |
EXP |
kaempferol results in decreased activity of ABCC1 protein kaempferol results in increased activity of ABCC1 protein kaempferol affects the reaction [ABCC1 protein results in increased uptake of estradiol-17 beta-glucuronide]; kaempferol inhibits the reaction [ABCC1 protein results in increased uptake of Leukotriene C4] kaempferol affects the activity of ABCC1 protein |
CTD |
PMID:11306701 PMID:15670588 PMID:15796199 |
|
NCBI chr16:15,949,616...16,143,062
Ensembl chr16:15,949,577...16,143,074 Ensembl chr16:15,949,577...16,143,074
|
|
G |
ACHE |
acetylcholinesterase (Cartwright blood group) |
multiple interactions |
ISO |
kaempferol inhibits the reaction [Chlorpyrifos results in decreased activity of ACHE protein] |
CTD |
PMID:30497708 |
|
NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974
|
|
G |
ACTA2 |
actin alpha 2, smooth muscle |
decreases expression |
ISO |
kaempferol results in decreased expression of ACTA2 protein |
CTD |
PMID:26683311 |
|
NCBI chr10:88,935,074...88,991,397
Ensembl chr10:88,935,074...88,991,339
|
|
G |
AFP |
alpha fetoprotein |
affects binding decreases expression |
ISO |
kaempferol binds to AFP protein kaempferol results in decreased expression of AFP protein |
CTD |
PMID:23013281 PMID:25349334 PMID:26683311 |
|
NCBI chr 4:73,436,221...73,456,174
Ensembl chr 4:73,431,138...73,456,174
|
|
G |
AHR |
aryl hydrocarbon receptor |
affects binding multiple interactions increases activity |
EXP ISO |
kaempferol binds to AHR protein kaempferol inhibits the reaction [beta-Naphthoflavone promotes the reaction [AHR protein binds to ARNT protein]]; kaempferol inhibits the reaction [beta-Naphthoflavone results in increased activity of [AHR protein binds to ARNT protein]]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [AHR protein binds to AIP protein]]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to ARNT protein]]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin results in increased localization of AHR protein] kaempferol results in increased activity of AHR protein kaempferol inhibits the reaction [Benzo(a)pyrene results in increased activity of AHR protein]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 enhancer]]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 promoter]]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1B1 enhancer]]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1B1 promoter]]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of AHR protein] |
CTD |
PMID:10359656 PMID:14644660 PMID:17012224 PMID:19034627 PMID:19794518 PMID:20450880 PMID:20846786 |
|
NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152
|
|
G |
AIP |
aryl hydrocarbon receptor interacting protein |
multiple interactions |
ISO |
kaempferol inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [AHR protein binds to AIP protein]] |
CTD |
PMID:20450880 |
|
NCBI chr11:67,468,179...67,491,103
Ensembl chr11:67,483,026...67,491,103
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation |
EXP ISO |
kaempferol inhibits the reaction [HGF protein results in increased phosphorylation of AKT1 protein]; kaempferol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of AKT1 protein] kaempferol results in decreased phosphorylation of AKT1 protein kaempferol inhibits the reaction [INS1 protein results in increased activity of AKT1 protein] |
CTD |
PMID:18591783 PMID:19244381 PMID:20438634 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
|
|
G |
ALOX12 |
arachidonate 12-lipoxygenase, 12S type |
decreases activity multiple interactions |
EXP |
kaempferol results in decreased activity of ALOX12 protein kaempferol inhibits the reaction [ALOX12 protein results in increased chemical synthesis of 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid] |
CTD |
PMID:17027136 |
|
NCBI chr17:6,993,791...7,010,754
Ensembl chr17:6,996,049...7,010,754
|
|
G |
ALOX5 |
arachidonate 5-lipoxygenase |
multiple interactions |
EXP |
kaempferol inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4] |
CTD |
PMID:18096136 |
|
NCBI chr10:45,374,209...45,446,121
Ensembl chr10:45,374,176...45,446,119
|
|
G |
APOE |
apolipoprotein E |
multiple interactions |
ISO |
kaempferol inhibits the reaction [APOE affects the expression of CD44 mRNA]; kaempferol inhibits the reaction [APOE affects the expression of CD44 protein]; kaempferol inhibits the reaction [APOE affects the expression of SPP1 mRNA]; kaempferol inhibits the reaction [APOE affects the expression of SPP1 protein] |
CTD |
PMID:22005275 |
|
NCBI chr19:44,905,796...44,909,393
Ensembl chr19:44,905,791...44,909,393
|
|
G |
APP |
amyloid beta precursor protein |
multiple interactions |
ISO |
kaempferol inhibits the reaction [APP protein binds to APP protein] |
CTD |
PMID:17323972 |
|
NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,550...26,171,128
|
|
G |
AR |
androgen receptor |
multiple interactions |
EXP |
kaempferol inhibits the reaction [Stanozolol binds to and results in increased activity of AR protein] |
CTD |
PMID:29162470 |
|
NCBI chr X:67,544,021...67,730,619
Ensembl chr X:67,544,021...67,730,619
|
|
G |
ARNT |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
ISO EXP |
kaempferol inhibits the reaction [beta-Naphthoflavone promotes the reaction [AHR protein binds to ARNT protein]]; kaempferol inhibits the reaction [beta-Naphthoflavone results in increased activity of [AHR protein binds to ARNT protein]]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to ARNT protein]] kaempferol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [ARNT protein binds to CYP1A1 enhancer]]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [ARNT protein binds to CYP1A1 promoter]]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [ARNT protein binds to CYP1B1 enhancer]]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [ARNT protein binds to CYP1B1 promoter]]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of ARNT protein] |
CTD |
PMID:17012224 PMID:20450880 PMID:20846786 |
|
NCBI chr 1:150,809,713...150,876,737
Ensembl chr 1:150,809,713...150,876,708
|
|
G |
ATM |
ATM serine/threonine kinase |
multiple interactions increases phosphorylation |
EXP |
Caffeine inhibits the reaction [kaempferol results in increased phosphorylation of ATM protein] |
CTD |
PMID:19028473 |
|
NCBI chr11:108,222,484...108,369,102
Ensembl chr11:108,222,832...108,369,102 Ensembl chr11:108,222,832...108,369,102
|
|
G |
B3GALT5 |
beta-1,3-galactosyltransferase 5 |
decreases expression |
EXP |
kaempferol results in decreased expression of B3GALT5 protein |
CTD |
PMID:22906706 |
|
NCBI chr21:39,612,940...39,673,137
Ensembl chr21:39,556,442...39,673,137
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
EXP ISO |
kaempferol results in increased expression of BAX protein kaempferol inhibits the reaction [propacetamol results in increased expression of BAX protein] kaempferol inhibits the reaction [Doxorubicin promotes the reaction [TP53 protein binds to BAX promoter]]; kaempferol inhibits the reaction [Doxorubicin results in increased expression of BAX mRNA] |
CTD |
PMID:19028473 PMID:22155320 PMID:29574133 |
|
NCBI chr19:48,954,825...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BBC3 |
BCL2 binding component 3 |
multiple interactions increases expression |
EXP |
Caffeine inhibits the reaction [kaempferol results in increased expression of BBC3 protein]; kaempferol promotes the reaction [BBC3 protein binds to BCL2L1 protein]; TP53 protein affects the reaction [kaempferol promotes the reaction [BBC3 protein binds to BCL2L1 protein]] |
CTD |
PMID:19028473 |
|
NCBI chr19:47,220,822...47,232,998
Ensembl chr19:47,220,822...47,232,766
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
decreases expression |
EXP |
kaempferol results in decreased expression of BCL2 protein |
CTD |
PMID:19028473 |
|
NCBI chr18:63,123,346...63,320,280
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BCL2A1 |
BCL2 related protein A1 |
multiple interactions |
EXP |
kaempferol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BCL2A1 mRNA] |
CTD |
PMID:20438634 |
|
NCBI chr15:79,960,892...79,971,196
Ensembl chr15:79,960,892...79,971,196
|
|
G |
BCL2L1 |
BCL2 like 1 |
multiple interactions |
EXP |
kaempferol promotes the reaction [BBC3 protein binds to BCL2L1 protein]; TP53 protein affects the reaction [kaempferol promotes the reaction [BBC3 protein binds to BCL2L1 protein]] |
CTD |
PMID:19028473 |
|
NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
|
|
G |
BMP2 |
bone morphogenetic protein 2 |
increases expression |
ISO |
kaempferol results in increased expression of BMP2 mRNA; kaempferol results in increased expression of BMP2 protein |
CTD |
PMID:23989061 |
|
NCBI chr20:6,767,686...6,780,246
Ensembl chr20:6,767,686...6,780,246
|
|
G |
BMP4 |
bone morphogenetic protein 4 |
increases expression |
ISO |
kaempferol results in increased expression of BMP4 mRNA |
CTD |
PMID:23989061 |
|
NCBI chr14:53,949,736...53,956,891
Ensembl chr14:53,949,736...53,958,761
|
|
G |
CALCR |
calcitonin receptor |
multiple interactions |
ISO |
kaempferol inhibits the reaction [TNFSF11 protein results in increased expression of CALCR mRNA] |
CTD |
PMID:16434028 |
|
NCBI chr 7:93,424,486...93,574,730
Ensembl chr 7:93,424,486...93,574,730 Ensembl chr 7:93,424,486...93,574,730
|
|
G |
CASP1 |
caspase 1 |
multiple interactions |
EXP |
kaempferol inhibits the reaction [IL32 protein results in increased expression of and results in increased activity of CASP1 protein] |
CTD |
PMID:28711657 |
|
NCBI chr11:105,025,443...105,035,591
Ensembl chr11:105,025,443...105,035,250
|
|
G |
CASP3 |
caspase 3 |
multiple interactions increases cleavage |
ISO EXP |
kaempferol inhibits the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; kaempferol promotes the reaction [Sulindac inhibits the reaction [1,2-Dimethylhydrazine results in decreased expression of CASP3 protein]] kaempferol inhibits the reaction [propacetamol results in increased cleavage of CASP3 protein]; kaempferol inhibits the reaction [Rotenone results in increased cleavage of CASP3 protein] kaempferol results in increased cleavage of CASP3 protein 3',4'-dihydroxyflavone analog inhibits the reaction [kaempferol results in increased cleavage of CASP3 protein]; kaempferol inhibits the reaction [Rotenone results in increased cleavage of CASP3 protein] |
CTD |
PMID:16014620 PMID:18331776 PMID:19028473 PMID:19397994 PMID:20594614 PMID:22155320 PMID:29574133 PMID:29999212 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
|
|
G |
CASP9 |
caspase 9 |
increases cleavage multiple interactions |
EXP |
kaempferol results in increased cleavage of CASP9 protein kaempferol inhibits the reaction [Rotenone results in increased cleavage of CASP9 protein] |
CTD |
PMID:18331776 PMID:20594614 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
kaempferol inhibits the reaction [Chlorpyrifos results in decreased activity of CAT protein]; kaempferol inhibits the reaction [Dietary Fats results in decreased activity of CAT protein]; kaempferol inhibits the reaction [Doxorubicin results in decreased activity of CAT protein] kaempferol inhibits the reaction [propacetamol results in decreased activity of CAT protein] |
CTD |
PMID:22155320 PMID:29574133 PMID:30372826 PMID:30497708 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCKAR |
cholecystokinin A receptor |
multiple interactions |
ISO |
kaempferol inhibits the reaction [8-sulfocholecystokinin octapeptide results in increased activity of CCKAR protein] |
CTD |
PMID:24630973 |
|
NCBI chr 4:26,481,396...26,490,484
Ensembl chr 4:26,481,396...26,490,484
|
|
G |
CCL2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO EXP |
kaempferol inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; kaempferol inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; kaempferol inhibits the reaction [TNF protein results in increased secretion of CCL2 protein] kaempferol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CCL2 mRNA] |
CTD |
PMID:16434028 PMID:20438634 PMID:31306686 |
|
NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,218...34,257,203
|
|
G |
CCL5 |
C-C motif chemokine ligand 5 |
multiple interactions |
EXP |
[Vitamin E co-treated with Quercetin co-treated with kaempferol co-treated with 3,4-dihydroxyphenylethanol] results in decreased expression of CCL5 mRNA |
CTD |
PMID:16797527 |
|
NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793
|
|
G |
CCN5 |
cellular communication network factor 5 |
increases expression multiple interactions |
EXP |
kaempferol results in increased expression of CCN5 mRNA ESR1 protein inhibits the reaction [kaempferol results in increased expression of CCN5 mRNA] |
CTD |
PMID:23384675 |
|
NCBI chr20:44,714,204...44,728,041
Ensembl chr20:44,714,844...44,728,509
|
|
G |
CCNB1 |
cyclin B1 |
decreases expression |
EXP |
kaempferol results in decreased expression of CCNB1 mRNA; kaempferol results in decreased expression of CCNB1 protein |
CTD |
PMID:18331776 PMID:19397994 |
|
NCBI chr 5:69,167,150...69,178,245
Ensembl chr 5:69,167,135...69,178,245
|
|
G |
CCND1 |
cyclin D1 |
multiple interactions |
EXP |
kaempferol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CCND1 mRNA] |
CTD |
PMID:20438634 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474 Ensembl chr11:69,641,156...69,654,474
|
|
G |
CD14 |
CD14 molecule |
multiple interactions |
EXP |
kaempferol inhibits the reaction [IL32 protein results in increased expression of CD14 mRNA]; kaempferol inhibits the reaction [IL32 protein results in increased expression of CD14 protein] |
CTD |
PMID:28711657 |
|
NCBI chr 5:140,631,732...140,633,701
Ensembl chr 5:140,631,728...140,633,701
|
|
G |
CD44 |
CD44 molecule (Indian blood group) |
multiple interactions |
ISO EXP |
kaempferol inhibits the reaction [APOE affects the expression of CD44 mRNA]; kaempferol inhibits the reaction [APOE affects the expression of CD44 protein] kaempferol inhibits the reaction [IL32 protein results in increased expression of CD44 protein] |
CTD |
PMID:22005275 PMID:28711657 |
|
NCBI chr11:35,139,168...35,232,402
Ensembl chr11:35,138,882...35,232,402 Ensembl chr11:35,138,882...35,232,402
|
|
G |
CDK1 |
cyclin dependent kinase 1 |
multiple interactions |
EXP |
kaempferol results in increased phosphorylation of and results in decreased activity of CDK1 protein |
CTD |
PMID:11322924 |
|
NCBI chr10:60,778,331...60,794,852
Ensembl chr10:60,778,331...60,794,852
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
increases expression |
EXP |
kaempferol results in increased expression of CDKN1A mRNA; kaempferol results in increased expression of CDKN1A protein |
CTD |
PMID:19397994 |
|
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,339 Ensembl chr 6:36,676,460...36,687,339
|
|
G |
CDKN2C |
cyclin dependent kinase inhibitor 2C |
decreases expression |
EXP |
kaempferol results in decreased expression of CDKN2C mRNA |
CTD |
PMID:18331776 |
|
NCBI chr 1:50,968,706...50,974,634
Ensembl chr 1:50,960,745...50,974,634
|
|
G |
CFTR |
CF transmembrane conductance regulator |
affects localization |
EXP |
kaempferol affects the localization of CFTR protein mutant form |
CTD |
PMID:15191910 |
|
NCBI chr 7:117,480,025...117,668,665
Ensembl chr 7:117,287,120...117,715,971 Ensembl chr 7:117,287,120...117,715,971
|
|
G |
CHEK1 |
checkpoint kinase 1 |
increases phosphorylation |
ISO |
kaempferol results in increased phosphorylation of CHEK1 protein |
CTD |
PMID:24595819 |
|
NCBI chr11:125,624,910...125,676,255
Ensembl chr11:125,625,665...125,676,255
|
|
G |
CHEK2 |
checkpoint kinase 2 |
increases phosphorylation |
ISO |
kaempferol results in increased phosphorylation of CHEK2 protein |
CTD |
PMID:24595819 |
|
NCBI chr22:28,687,743...28,741,866
Ensembl chr22:28,687,743...28,742,422
|
|
G |
CHUK |
component of inhibitor of nuclear factor kappa B kinase complex |
decreases phosphorylation multiple interactions |
EXP ISO |
kaempferol results in decreased phosphorylation of CHUK protein kaempferol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of CHUK protein] |
CTD |
PMID:17184768 PMID:30769083 |
|
NCBI chr10:100,188,300...100,229,610
Ensembl chr10:100,188,300...100,229,596
|
|
G |
COL10A1 |
collagen type X alpha 1 chain |
increases expression |
ISO |
kaempferol results in increased expression of COL10A1 mRNA |
CTD |
PMID:23989061 |
|
NCBI chr 6:116,118,909...116,219,937
Ensembl chr 6:116,118,909...116,158,747
|
|
G |
COL2A1 |
collagen type II alpha 1 chain |
increases expression |
ISO |
kaempferol results in increased expression of COL2A1 mRNA |
CTD |
PMID:23989061 |
|
NCBI chr12:47,972,967...48,006,212
Ensembl chr12:47,972,967...48,004,554
|
|
G |
CPT1A |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
kaempferol inhibits the reaction [Dietary Fats results in decreased expression of CPT1A mRNA] |
CTD |
PMID:30372826 |
|
NCBI chr11:68,754,620...68,844,410
Ensembl chr11:68,754,620...68,844,410
|
|
G |
CRP |
C-reactive protein |
decreases expression |
EXP |
kaempferol results in decreased expression of CRP mRNA; kaempferol results in decreased expression of CRP protein |
CTD |
PMID:17184768 |
|
NCBI chr 1:159,712,289...159,714,589
Ensembl chr 1:159,712,289...159,714,589
|
|
G |
CS |
citrate synthase |
increases activity |
ISO |
kaempferol results in increased activity of CS protein |
CTD |
PMID:31306686 |
|
NCBI chr12:56,271,699...56,300,330
Ensembl chr12:56,271,699...56,300,391
|
|
G |
CSF2 |
colony stimulating factor 2 |
multiple interactions increases secretion |
EXP |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [kaempferol results in increased secretion of CSF2 protein]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [kaempferol results in increased secretion of CSF2 protein]; bisindolylmaleimide I inhibits the reaction [kaempferol results in increased secretion of CSF2 protein]; Brefeldin A inhibits the reaction [kaempferol results in increased secretion of CSF2 protein]; Colchicine inhibits the reaction [kaempferol results in increased secretion of CSF2 protein]; Cytochalasin B inhibits the reaction [kaempferol results in increased secretion of CSF2 protein]; Egtazic Acid inhibits the reaction [kaempferol results in increased secretion of CSF2 protein]; Monensin inhibits the reaction [kaempferol results in increased secretion of CSF2 protein]; Nocodazole inhibits the reaction [kaempferol results in increased secretion of CSF2 protein]; U 0126 inhibits the reaction [kaempferol results in increased secretion of CSF2 protein] |
CTD |
PMID:18346843 |
|
NCBI chr 5:132,073,789...132,076,170
Ensembl chr 5:132,073,789...132,076,170
|
|
G |
CTNNB1 |
catenin beta 1 |
multiple interactions |
ISO |
kaempferol promotes the reaction [Sulindac inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of CTNNB1 protein]] |
CTD |
PMID:29999212 |
|
NCBI chr 3:41,199,422...41,240,445
Ensembl chr 3:41,194,741...41,260,096
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions |
EXP |
kaempferol inhibits the reaction [IL32 protein results in increased expression of CXCL8 mRNA]; kaempferol inhibits the reaction [IL32 protein results in increased secretion of CXCL8 protein]; kaempferol inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL8 protein]; kaempferol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CXCL8 mRNA] |
CTD |
PMID:20438634 PMID:28711657 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,541...73,743,716
|
|
G |
CYCS |
cytochrome c, somatic |
multiple interactions affects localization |
EXP |
Caffeine inhibits the reaction [kaempferol affects the localization of CYCS protein] |
CTD |
PMID:19028473 |
|
NCBI chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260 Ensembl chr 7:25,118,656...25,125,260
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
multiple interactions decreases activity increases activity increases expression |
EXP ISO |
[Quercetin co-treated with kaempferol co-treated with 3-methylquercetin co-treated with ginkgolide A co-treated with ginkgolide B co-treated with ginkgolide C co-treated with ginkgolide J co-treated with bilobalide] affects the activity of CYP1A1 protein; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin co-treated with ginkgolide A co-treated with ginkgolide B co-treated with ginkgolide C co-treated with ginkgolide J co-treated with bilobalide] inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1A1 protein]; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin co-treated with ginkgolide A co-treated with ginkgolide B co-treated with ginkgolide C co-treated with ginkgolide J co-treated with bilobalide] inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin] affects the activity of CYP1A1 protein; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin] inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1A1 protein]; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin] inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; kaempferol inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1A1 protein]; kaempferol inhibits the reaction [Smoke results in increased expression of CYP1A1 mRNA]; kaempferol inhibits the reaction [Smoke results in increased expression of CYP1A1 protein]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 enhancer]]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 promoter]]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [ARNT protein binds to CYP1A1 enhancer]]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [ARNT protein binds to CYP1A1 promoter]]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [ESR1 protein binds to CYP1A1 enhancer]]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]; kaempferol promotes the reaction [Quercetin results in increased expression of CYP1A1 mRNA] kaempferol inhibits the reaction [beta-Naphthoflavone results in increased activity of CYP1A1 protein]; kaempferol inhibits the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA] kaempferol results in decreased activity of CYP1A1 protein kaempferol results in increased activity of CYP1A1 protein kaempferol results in increased expression of CYP1A1 mRNA |
CTD |
PMID:10359656 PMID:11454723 PMID:16271822 PMID:17012224 PMID:20846786 PMID:20930378 PMID:21053930 PMID:21256954 PMID:21329749 PMID:21482471 PMID:29584932 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
increases expression decreases activity multiple interactions |
EXP ISO |
kaempferol results in increased expression of CYP1A2 mRNA kaempferol results in decreased activity of CYP1A2 protein kaempferol inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA] kaempferol results in increased expression of and results in increased activity of CYP1A2 protein |
CTD |
PMID:18421621 PMID:19034627 PMID:20806393 PMID:21053930 PMID:21256954 PMID:29753067 |
|
NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
decreases expression multiple interactions decreases activity |
EXP |
kaempferol results in decreased expression of CYP1B1 mRNA kaempferol binds to and results in decreased activity of CYP1B1 protein; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1B1 enhancer]]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1B1 promoter]]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [ARNT protein binds to CYP1B1 enhancer]]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [ARNT protein binds to CYP1B1 promoter]]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [ESR1 protein binds to CYP1B1 enhancer]]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA] kaempferol results in decreased activity of CYP1B1 protein |
CTD |
PMID:16271822 PMID:19794518 PMID:20846786 PMID:21053930 PMID:21482471 |
|
NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902
|
|
G |
CYP2C9 |
cytochrome P450 family 2 subfamily C member 9 |
multiple interactions decreases activity |
EXP |
kaempferol inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] kaempferol results in decreased activity of CYP2C9 protein |
CTD |
PMID:21053930 PMID:29753067 |
|
NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
multiple interactions |
ISO |
kaempferol inhibits the reaction [propacetamol results in increased expression of CYP2E1 protein] |
CTD |
PMID:29574133 |
|
NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
increases expression decreases activity multiple interactions |
EXP |
kaempferol results in increased expression of CYP3A4 mRNA kaempferol results in decreased activity of CYP3A4 protein [kaempferol results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; kaempferol inhibits the reaction [CYP3A4 protein results in increased degradation of Hydrocortisone] |
CTD |
PMID:15266218 PMID:16442130 PMID:21053930 PMID:25455453 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
DHRS11 |
dehydrogenase/reductase 11 |
decreases activity |
EXP |
kaempferol results in decreased activity of DHRS11 protein |
CTD |
PMID:30926317 |
|
NCBI chr17:36,591,846...36,600,804
Ensembl chr17:36,591,879...36,600,804
|
|
G |
DIO2 |
iodothyronine deiodinase 2 |
increases activity increases expression multiple interactions |
EXP |
kaempferol results in increased activity of DIO2 protein kaempferol results in increased expression of DIO2 mRNA kaempferol promotes the reaction [DIO2 protein results in increased activity of and results in increased abundance of Triiodothyronine] |
CTD |
PMID:17327447 |
|
NCBI chr14:80,197,526...80,231,057
Ensembl chr14:80,197,527...80,387,757 Ensembl chr14:80,197,527...80,387,757
|
|
G |
DUOX1 |
dual oxidase 1 |
multiple interactions |
EXP |
kaempferol inhibits the reaction [Paraquat results in increased expression of DUOX1 mRNA] |
CTD |
PMID:25177032 |
|
NCBI chr15:45,129,994...45,165,578
Ensembl chr15:45,129,933...45,165,576
|
|
G |
EP300 |
E1A binding protein p300 |
multiple interactions |
EXP |
kaempferol promotes the reaction [Oxygen deficiency promotes the reaction [HIF1A protein binds to EP300 protein]] |
CTD |
PMID:20153296 |
|
NCBI chr22:41,092,592...41,180,077
Ensembl chr22:41,092,592...41,180,077
|
|
G |
ESR1 |
estrogen receptor 1 |
multiple interactions affects binding increases expression increases activity |
EXP ISO |
ESR1 protein inhibits the reaction [kaempferol results in increased expression of CCN5 mRNA]; ESR1 protein inhibits the reaction [kaempferol results in increased expression of PGR mRNA]; ESR1 protein inhibits the reaction [kaempferol results in increased expression of TFF1 mRNA]; Estradiol affects the reaction [kaempferol results in increased activity of ESR1 protein]; kaempferol binds to and results in increased activity of ESR1 protein; kaempferol inhibits the reaction [Estradiol binds to ESR1 protein]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [ESR1 protein binds to CYP1A1 enhancer]]; kaempferol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [ESR1 protein binds to CYP1B1 enhancer]]; kaempferol promotes the reaction [ESR1 protein binds to GREB1 enhancer]; kaempferol results in increased expression of and results in increased localization of ESR1 protein kaempferol binds to ESR1 protein kaempferol results in increased expression of ESR1 mRNA |
CTD |
PMID:9751507 PMID:14579009 PMID:14706564 PMID:15182386 PMID:16118406 PMID:19913605 PMID:20846786 PMID:23384675 PMID:29162470 |
|
NCBI chr 6:151,654,148...152,129,619
Ensembl chr 6:151,656,691...152,129,619
|
|
G |
ESR2 |
estrogen receptor 2 |
multiple interactions increases expression affects binding increases activity |
EXP ISO |
Estradiol affects the reaction [kaempferol results in increased activity of ESR2 protein]; kaempferol binds to and results in increased activity of ESR2 protein; kaempferol inhibits the reaction [Estradiol binds to ESR2 protein] kaempferol results in increased expression of ESR2 protein ESR2 protein alternative form inhibits the reaction [kaempferol results in increased expression of ESR2 protein] kaempferol binds to ESR2 protein |
CTD |
PMID:9751507 PMID:12224631 PMID:14706564 PMID:15182386 PMID:16118406 PMID:18937077 PMID:19913605 PMID:27634370 |
|
NCBI chr14:64,226,707...64,338,631
Ensembl chr14:64,084,232...64,338,112
|
|
G |
FBP1 |
fructose-bisphosphatase 1 |
decreases expression |
EXP |
kaempferol results in decreased expression of FBP1 mRNA |
CTD |
PMID:18331776 |
|
NCBI chr 9:94,603,133...94,640,263
Ensembl chr 9:94,603,133...94,640,249
|
|
G |
FN1 |
fibronectin 1 |
increases expression |
EXP |
kaempferol results in increased expression of FN1 protein |
CTD |
PMID:26408079 |
|
NCBI chr 2:215,360,862...215,436,167
Ensembl chr 2:215,360,440...215,436,073
|
|
G |
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO EXP |
kaempferol inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA] kaempferol inhibits the reaction [TNF protein results in increased activity of [FOS protein binds to JUN protein]] |
CTD |
PMID:15322261 PMID:16434028 |
|
NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230
|
|
G |
GADD45B |
growth arrest and DNA damage inducible beta |
increases expression |
EXP |
kaempferol results in increased expression of GADD45B mRNA; kaempferol results in increased expression of GADD45B protein |
CTD |
PMID:18331776 |
|
NCBI chr19:2,476,127...2,478,259
Ensembl chr19:2,476,122...2,478,259
|
|
G |
GCLC |
glutamate-cysteine ligase catalytic subunit |
increases expression multiple interactions |
EXP ISO |
kaempferol results in increased expression of GCLC mRNA kaempferol affects the reaction [propacetamol affects the expression of GCLC protein] |
CTD |
PMID:11864778 PMID:29574133 |
|
NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970
|
|
G |
GPT |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
kaempferol inhibits the reaction [Ethanol results in increased activity of GPT protein]; kaempferol inhibits the reaction [propacetamol results in increased activity of GPT protein] |
CTD |
PMID:29574133 PMID:31785310 |
|
NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174
|
|
G |
GREB1 |
growth regulating estrogen receptor binding 1 |
multiple interactions increases expression |
EXP |
fulvestrant inhibits the reaction [kaempferol results in increased expression of GREB1 mRNA]; kaempferol promotes the reaction [ESR1 protein binds to GREB1 enhancer]; kaempferol promotes the reaction [NCOA3 protein binds to GREB1 enhancer] |
CTD |
PMID:20846786 |
|
NCBI chr 2:11,481,675...11,642,788
Ensembl chr 2:11,482,341...11,642,788
|
|
G |
GSK3B |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
kaempferol inhibits the reaction [Chlorpyrifos results in increased expression of GSK3B mRNA] |
CTD |
PMID:30497708 |
|
NCBI chr 3:119,821,321...120,095,823
Ensembl chr 3:119,821,323...120,094,417 Ensembl chr 3:119,821,323...120,094,417 Ensembl chr 3:119,821,323...120,094,417
|
|
G |
GSTA1 |
glutathione S-transferase alpha 1 |
increases expression |
EXP |
kaempferol results in increased expression of GSTA1 mRNA |
CTD |
PMID:21256954 |
|
NCBI chr 6:52,791,371...52,803,827
Ensembl chr 6:52,791,371...52,803,860
|
|
G |
GSTM2 |
glutathione S-transferase mu 2 |
multiple interactions |
EXP |
[Quercetin co-treated with kaempferol] results in increased expression of GSTM2 mRNA |
CTD |
PMID:25111660 |
|
NCBI chr 1:109,668,057...109,683,997
Ensembl chr 1:109,668,022...109,709,551
|
|
G |
GSTP1 |
glutathione S-transferase pi 1 |
decreases activity |
EXP |
kaempferol results in decreased activity of GSTP1 protein |
CTD |
PMID:15041478 |
|
NCBI chr11:67,583,812...67,586,653
Ensembl chr11:67,583,742...67,586,656 Ensembl chr11:67,583,742...67,586,656
|
|
G |
H2AX |
H2A.X variant histone |
increases phosphorylation increases expression |
EXP ISO |
kaempferol results in increased phosphorylation of H2AX protein kaempferol results in increased expression of H2AX protein |
CTD |
PMID:19028473 PMID:24595819 |
|
NCBI chr11:119,093,874...119,095,465
Ensembl chr11:119,093,854...119,095,467
|
|
G |
HBB |
hemoglobin subunit beta |
multiple interactions |
EXP |
kaempferol inhibits the reaction [HBB gene polymorphism results in increased susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] |
CTD |
PMID:14691983 |
|
NCBI chr11:5,225,464...5,227,071
Ensembl chr11:5,225,464...5,229,395
|
|
G |
HCAR3 |
hydroxycarboxylic acid receptor 3 |
multiple interactions |
ISO |
kaempferol inhibits the reaction [Ethanol results in decreased expression of HCAR2 protein] |
CTD |
PMID:31785310 |
|
NCBI chr12:122,714,756...122,716,811
Ensembl chr12:122,714,756...122,716,811
|
|
G |
HGF |
hepatocyte growth factor |
multiple interactions |
EXP |
kaempferol inhibits the reaction [HGF protein results in increased phosphorylation of AKT1 protein]; kaempferol inhibits the reaction [HGF protein results in increased phosphorylation of MET protein] |
CTD |
PMID:19244381 |
|
NCBI chr 7:81,699,006...81,770,438
Ensembl chr 7:81,699,010...81,770,438
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
EXP |
kaempferol promotes the reaction [Oxygen deficiency promotes the reaction [HIF1A protein binds to EP300 protein]] |
CTD |
PMID:20153296 |
|
NCBI chr14:61,695,513...61,748,259
Ensembl chr14:61,695,513...61,748,259
|
|
G |
HMOX1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
Hemin promotes the reaction [kaempferol results in increased expression of HMOX1 protein]; HMOX1 protein promotes the reaction [kaempferol inhibits the reaction [Lipopolysaccharides results in increased activity of NOS2 protein]]; kaempferol affects the reaction [propacetamol affects the expression of HMOX1 protein] [pterostilbene co-treated with kaempferol] results in increased expression of HMOX1 mRNA kaempferol results in increased expression of HMOX1 mRNA; kaempferol results in increased expression of HMOX1 protein |
CTD |
PMID:14563492 PMID:16303981 PMID:19265714 PMID:25111660 PMID:29574133 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,207 Ensembl chr22:35,380,361...35,394,207
|
|
G |
ICAM1 |
intercellular adhesion molecule 1 |
multiple interactions |
EXP |
kaempferol inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of ICAM1 protein]; kaempferol inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; kaempferol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:15322261 PMID:16987811 PMID:18394220 |
|
NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615
|
|
G |
IFNG |
interferon gamma |
multiple interactions |
EXP |
kaempferol inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of ICAM1 protein]; kaempferol inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; kaempferol inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of PTGS2 protein]; kaempferol inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of SELE protein]; kaempferol inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of VCAM1 protein] |
CTD |
PMID:18394220 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
ISO EXP |
kaempferol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B mRNA]; kaempferol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] kaempferol inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of ICAM1 protein]; kaempferol inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; kaempferol inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of PTGS2 protein]; kaempferol inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of SELE protein]; kaempferol inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of VCAM1 protein]; kaempferol inhibits the reaction [IL1B protein results in increased expression of MUC5AC mRNA]; kaempferol inhibits the reaction [IL1B protein results in increased phosphorylation of MAP3K7 protein]; kaempferol inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein]; kaempferol inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein]; kaempferol inhibits the reaction [IL1B protein results in increased phosphorylation of NFKBIA protein]; kaempferol inhibits the reaction [IL1B protein results in increased ubiquitination of IRAK1 protein]; kaempferol inhibits the reaction [IL1B protein results in increased ubiquitination of TRAF6 protein]; kaempferol inhibits the reaction [IL32 protein results in increased expression of IL1B mRNA]; kaempferol inhibits the reaction [IL32 protein results in increased secretion of IL1B protein]; kaempferol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL1B protein] |
CTD |
PMID:15985724 PMID:18394220 PMID:18946510 PMID:19367675 PMID:28711657 PMID:30769083 |
|
NCBI chr 2:112,829,751...112,836,843
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL32 |
interleukin 32 |
multiple interactions |
EXP |
kaempferol inhibits the reaction [IL32 protein results in increased expression of and results in increased activity of CASP1 protein]; kaempferol inhibits the reaction [IL32 protein results in increased expression of CD14 mRNA]; kaempferol inhibits the reaction [IL32 protein results in increased expression of CD14 protein]; kaempferol inhibits the reaction [IL32 protein results in increased expression of CD44 protein]; kaempferol inhibits the reaction [IL32 protein results in increased expression of CXCL8 mRNA]; kaempferol inhibits the reaction [IL32 protein results in increased expression of IL1B mRNA]; kaempferol inhibits the reaction [IL32 protein results in increased expression of ITGAM mRNA]; kaempferol inhibits the reaction [IL32 protein results in increased expression of ITGAM protein]; kaempferol inhibits the reaction [IL32 protein results in increased expression of TNF mRNA]; kaempferol inhibits the reaction [IL32 protein results in increased expression of TSLP mRNA]; kaempferol inhibits the reaction [IL32 protein results in increased secretion of CXCL8 protein]; kaempferol inhibits the reaction [IL32 protein results in increased secretion of IL1B protein]; kaempferol inhibits the reaction [IL32 protein results in increased secretion of TNF protein]; kaempferol inhibits the reaction [IL32 protein results in increased secretion of TSLP protein] |
CTD |
PMID:28711657 |
|
NCBI chr16:3,065,403...3,069,530
Ensembl chr16:3,065,297...3,082,192
|
|
G |
IL4 |
interleukin 4 |
multiple interactions |
EXP |
kaempferol inhibits the reaction [Calcimycin results in increased expression of IL4 mRNA] |
CTD |
PMID:12789233 |
|
NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678
|
|
G |
IL5 |
interleukin 5 |
multiple interactions |
EXP |
[Vitamin E co-treated with Quercetin co-treated with kaempferol co-treated with 3,4-dihydroxyphenylethanol] results in decreased expression of IL5 mRNA; kaempferol inhibits the reaction [Calcimycin results in increased expression of IL5 mRNA] |
CTD |
PMID:12789233 PMID:16797527 |
|
NCBI chr 5:132,539,194...132,556,864
Ensembl chr 5:132,541,445...132,556,838
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
EXP ISO |
[Vitamin E co-treated with Quercetin co-treated with kaempferol co-treated with 3,4-dihydroxyphenylethanol] results in decreased expression of IL6 mRNA; kaempferol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; kaempferol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL6 mRNA] kaempferol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; kaempferol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; kaempferol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; kaempferol inhibits the reaction [propacetamol results in increased expression of IL6 protein]; kaempferol inhibits the reaction [TNF protein results in increased secretion of IL6 protein] |
CTD |
PMID:16434028 PMID:16797527 PMID:20438634 PMID:28711657 PMID:29574133 PMID:30769083 |
|
NCBI chr 7:22,725,889...22,732,002
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
IRAK1 |
interleukin 1 receptor associated kinase 1 |
multiple interactions |
EXP |
kaempferol inhibits the reaction [IL1B protein results in increased ubiquitination of IRAK1 protein]; kaempferol inhibits the reaction [Lipopolysaccharides results in increased ubiquitination of IRAK1 protein] |
CTD |
PMID:30769083 |
|
NCBI chr X:154,010,507...154,019,984
Ensembl chr X:154,010,506...154,019,902
|
|
G |
ITGAM |
integrin subunit alpha M |
multiple interactions |
EXP |
kaempferol inhibits the reaction [IL32 protein results in increased expression of ITGAM mRNA]; kaempferol inhibits the reaction [IL32 protein results in increased expression of ITGAM protein] |
CTD |
PMID:28711657 |
|
NCBI chr16:31,259,975...31,332,877
Ensembl chr16:31,259,967...31,332,892
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
kaempferol inhibits the reaction [Rotenone results in increased phosphorylation of JUN protein]; kaempferol inhibits the reaction [TNF protein results in increased activity of [FOS protein binds to JUN protein]]; kaempferol inhibits the reaction [TNF protein results in increased expression of JUN mRNA] |
CTD |
PMID:15322261 PMID:20594614 |
|
NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,780,791...58,784,047 Ensembl chr 1:58,780,791...58,784,047
|
|
G |
KMT2A |
lysine methyltransferase 2A |
increases mutagenesis |
EXP |
kaempferol results in increased mutagenesis of KMT2A gene |
CTD |
PMID:17468513 |
|
NCBI chr11:118,436,492...118,526,832
Ensembl chr11:118,436,490...118,526,832
|
|
G |
LAMB2 |
laminin subunit beta 2 |
increases expression |
EXP |
kaempferol results in increased expression of LAMB2 protein |
CTD |
PMID:26408079 |
|
NCBI chr 3:49,121,114...49,133,066
Ensembl chr 3:49,121,114...49,133,118
|
|
G |
MAP3K7 |
mitogen-activated protein kinase kinase kinase 7 |
multiple interactions |
EXP |
kaempferol inhibits the reaction [IL1B protein results in increased phosphorylation of MAP3K7 protein] |
CTD |
PMID:30769083 |
|
NCBI chr 6:90,513,579...90,587,072
Ensembl chr 6:90,513,573...90,587,072
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
increases activity increases phosphorylation multiple interactions |
ISO EXP |
kaempferol results in increased activity of MAPK1 protein kaempferol results in increased phosphorylation of MAPK1 protein 3',4'-dihydroxyflavone analog inhibits the reaction [kaempferol results in increased phosphorylation of MAPK1 protein]; kaempferol inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein]; kaempferol inhibits the reaction [Paraquat results in increased phosphorylation of MAPK1 protein] kaempferol inhibits the reaction [Lipopolysaccharides results in increased expression of MAPK1 protein modified form]; kaempferol inhibits the reaction [propacetamol results in increased phosphorylation of MAPK1 protein] kaempferol inhibits the reaction [Doxorubicin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:15832817 PMID:16014620 PMID:18346843 PMID:19265714 PMID:19367675 PMID:22155320 PMID:25177032 PMID:29574133 PMID:30499162 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,754,500...21,867,680 Ensembl chr22:21,754,500...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
increases activity increases phosphorylation multiple interactions |
ISO EXP |
kaempferol results in increased activity of MAPK3 protein kaempferol results in increased phosphorylation of MAPK3 protein 3',4'-dihydroxyflavone analog inhibits the reaction [kaempferol results in increased phosphorylation of MAPK3 protein]; kaempferol inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein]; kaempferol inhibits the reaction [Paraquat results in increased phosphorylation of MAPK3 protein] kaempferol inhibits the reaction [Lipopolysaccharides results in increased expression of MAPK3 protein modified form]; kaempferol inhibits the reaction [propacetamol results in increased phosphorylation of MAPK3 protein] kaempferol inhibits the reaction [Doxorubicin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:15832817 PMID:16014620 PMID:18346843 PMID:19265714 PMID:19367675 PMID:22155320 PMID:25177032 PMID:29574133 PMID:30499162 |
|
NCBI chr16:30,114,105...30,123,309
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
increases phosphorylation |
EXP |
kaempferol results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:30499162 |
|
NCBI chr10:48,306,673...48,439,360
Ensembl chr10:48,306,639...48,439,360
|
|
G |
MAPK9 |
mitogen-activated protein kinase 9 |
increases phosphorylation |
EXP |
kaempferol results in increased phosphorylation of MAPK9 protein |
CTD |
PMID:30499162 |
|
NCBI chr 5:180,233,143...180,292,083
Ensembl chr 5:180,233,143...180,292,099
|
|
G |
MET |
MET proto-oncogene, receptor tyrosine kinase |
multiple interactions |
EXP |
kaempferol inhibits the reaction [HGF protein results in increased phosphorylation of MET protein] |
CTD |
PMID:19244381 |
|
NCBI chr 7:116,672,196...116,798,386
Ensembl chr 7:116,672,196...116,798,386 Ensembl chr 7:116,672,196...116,798,386
|
|
G |
MMP2 |
matrix metallopeptidase 2 |
multiple interactions decreases expression |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [kaempferol results in decreased expression of MMP2 protein]; kaempferol results in decreased expression of and results in decreased activity of MMP2 protein |
CTD |
PMID:26408079 PMID:30499162 |
|
NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691
|
|
G |
MT2A |
metallothionein 2A |
increases expression |
EXP |
kaempferol results in increased expression of MT2A mRNA |
CTD |
PMID:10656621 |
|
NCBI chr16:56,608,584...56,609,497
Ensembl chr16:56,608,584...56,609,497
|
|
G |
MUC5AC |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
EXP |
kaempferol inhibits the reaction [IL1B protein results in increased expression of MUC5AC mRNA]; kaempferol inhibits the reaction [Paraquat results in increased expression of MUC5AC mRNA] |
CTD |
PMID:19367675 PMID:25177032 |
|
NCBI chr11:1,157,953...1,201,138
Ensembl chr11:1,157,953...1,201,138
|
|
G |
NANOG |
Nanog homeobox |
increases expression |
ISO |
kaempferol results in increased expression of NANOG protein |
CTD |
PMID:26683311 |
|
NCBI chr12:7,789,402...7,799,146
Ensembl chr12:7,787,794...7,799,146
|
|
G |
NCOA3 |
nuclear receptor coactivator 3 |
multiple interactions |
EXP |
kaempferol promotes the reaction [NCOA3 protein binds to GREB1 enhancer] |
CTD |
PMID:20846786 |
|
NCBI chr20:47,501,887...47,656,872
Ensembl chr20:47,501,887...47,656,877
|
|
G |
NFE2L2 |
nuclear factor, erythroid 2 like 2 |
multiple interactions increases expression |
EXP ISO |
[kaempferol co-treated with Quercetin] results in increased expression of NFE2L2 mRNA; kaempferol inhibits the reaction [Benzo(a)pyrene results in increased expression of NFE2L2 mRNA] kaempferol inhibits the reaction [Chlorpyrifos results in decreased expression of NFE2L2 mRNA] kaempferol affects the reaction [propacetamol affects the expression of NFE2L2 protein] kaempferol results in increased expression of NFE2L2 mRNA |
CTD |
PMID:21256954 PMID:25111660 PMID:29574133 PMID:30497708 |
|
NCBI chr 2:177,230,303...177,265,131
Ensembl chr 2:177,227,595...177,392,697
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
decreases phosphorylation multiple interactions |
EXP |
kaempferol results in decreased phosphorylation of NFKBIA protein kaempferol inhibits the reaction [IL1B protein results in increased phosphorylation of NFKBIA protein]; kaempferol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased degradation of NFKBIA protein] |
CTD |
PMID:17184768 PMID:20438634 PMID:30769083 |
|
NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,511...35,404,749 Ensembl chr14:35,401,511...35,404,749
|
|
G |
NOS2 |
nitric oxide synthase 2 |
decreases expression multiple interactions |
EXP ISO |
kaempferol results in decreased expression of NOS2 mRNA; kaempferol results in decreased expression of NOS2 protein Hemin promotes the reaction [kaempferol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; HMOX1 protein promotes the reaction [kaempferol inhibits the reaction [Lipopolysaccharides results in increased activity of NOS2 protein]]; kaempferol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]; kaempferol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; kaempferol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; PPARG protein affects the reaction [kaempferol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]]; tin protoporphyrin IX inhibits the reaction [kaempferol inhibits the reaction [Lipopolysaccharides results in increased activity of NOS2 protein]] kaempferol inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein] |
CTD |
PMID:11343698 PMID:12512693 PMID:14563492 PMID:15832817 PMID:16934226 PMID:17177504 PMID:17184768 PMID:18274639 PMID:18394220 PMID:19352036 PMID:30769083 PMID:31306686 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NOX4 |
NADPH oxidase 4 |
multiple interactions |
EXP |
kaempferol inhibits the reaction [Paraquat results in increased expression of NOX4 mRNA] |
CTD |
PMID:25177032 |
|
NCBI chr11:89,324,353...89,589,557
Ensembl chr11:89,324,353...89,498,187
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
[pterostilbene co-treated with kaempferol] results in increased expression of NQO1 protein; [Quercetin co-treated with kaempferol] results in increased expression of NQO1 protein |
CTD |
PMID:25111660 |
|
NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
multiple interactions increases expression increases activity |
EXP ISO |
[kaempferol results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA kaempferol results in increased expression of NR1I2 mRNA |
CTD |
PMID:19034627 PMID:25455453 PMID:26238175 PMID:29933105 |
|
NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,485
|
|
G |
NR1I3 |
nuclear receptor subfamily 1 group I member 3 |
increases activity |
EXP |
kaempferol results in increased activity of NR1I3 protein |
CTD |
PMID:19034627 |
|
NCBI chr 1:161,229,666...161,238,623
Ensembl chr 1:161,229,666...161,238,302 Ensembl chr 1:161,229,666...161,238,302
|
|
G |
OCLN |
occludin |
multiple interactions |
ISO |
kaempferol inhibits the reaction [Ethanol results in decreased expression of OCLN protein] |
CTD |
PMID:31785310 |
|
NCBI chr 5:69,492,547...69,558,104
Ensembl chr 5:69,492,292...69,558,104
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO EXP |
kaempferol inhibits the reaction [Doxorubicin results in increased cleavage of PARP1 protein] kaempferol results in increased cleavage of PARP1 protein 3',4'-dihydroxyflavone analog inhibits the reaction [kaempferol results in increased cleavage of PARP1 protein] |
CTD |
PMID:16014620 PMID:22155320 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,691...226,408,093 Ensembl chr 1:226,360,691...226,408,093
|
|
G |
PCNA |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
kaempferol promotes the reaction [Sulindac inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of PCNA protein]] |
CTD |
PMID:29999212 |
|
NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626
|
|
G |
PGR |
progesterone receptor |
affects binding increases expression multiple interactions |
EXP |
kaempferol binds to PGR protein kaempferol results in increased expression of PGR mRNA ESR1 protein inhibits the reaction [kaempferol results in increased expression of PGR mRNA]; kaempferol inhibits the reaction [Progesterone binds to PGR protein] |
CTD |
PMID:14579009 PMID:23384675 |
|
NCBI chr11:101,029,624...101,130,681
Ensembl chr11:101,029,624...101,129,813
|
|
G |
POU5F1 |
POU class 5 homeobox 1 |
decreases expression increases expression |
EXP ISO |
kaempferol results in decreased expression of POU5F1 protein kaempferol results in increased expression of POU5F1 protein |
CTD |
PMID:22906706 PMID:26683311 |
|
NCBI chr 6:31,164,337...31,170,682
Ensembl chr 6:31,164,337...31,180,731
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions increases expression |
ISO EXP |
kaempferol binds to and results in increased activity of PPARG protein; kaempferol inhibits the reaction [rosiglitazone binds to and results in increased activity of PPARG protein]; PPARG protein affects the reaction [kaempferol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]]; PPARG protein affects the reaction [kaempferol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]] kaempferol results in increased expression of PPARG mRNA; kaempferol results in increased expression of PPARG protein |
CTD |
PMID:11343698 PMID:18262572 PMID:25765892 |
|
NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
|
|
G |
PPARGC1A |
PPARG coactivator 1 alpha |
increases expression |
EXP |
kaempferol results in increased expression of PPARGC1A mRNA |
CTD |
PMID:17327447 |
|
NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089
|
|
G |
PSCA |
prostate stem cell antigen |
decreases expression |
EXP |
kaempferol results in decreased expression of PSCA mRNA |
CTD |
PMID:18331776 |
|
NCBI chr 8:142,670,297...142,682,725
Ensembl chr 8:142,670,308...142,682,725
|
|
G |
PTGES |
prostaglandin E synthase |
multiple interactions |
ISO |
kaempferol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGES mRNA] |
CTD |
PMID:21341175 |
|
NCBI chr 9:129,738,349...129,753,042
Ensembl chr 9:129,738,331...129,753,042
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions decreases expression |
ISO EXP |
kaempferol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; kaempferol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; kaempferol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; PPARG protein affects the reaction [kaempferol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]] kaempferol inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of PTGS2 protein]; kaempferol inhibits the reaction [TGFA protein results in increased expression of PTGS2 mRNA] kaempferol results in decreased expression of PTGS2 mRNA; kaempferol results in decreased expression of PTGS2 protein |
CTD |
PMID:10783318 PMID:11343698 PMID:17184768 PMID:18394220 PMID:19352036 PMID:21341175 PMID:30769083 PMID:31306686 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,423
|
|
G |
PYCARD |
PYD and CARD domain containing |
multiple interactions |
EXP |
kaempferol inhibits the reaction [Uric Acid promotes the reaction [PYCARD protein binds to PYCARD protein]] |
CTD |
PMID:29960001 |
|
NCBI chr16:31,201,486...31,202,760
Ensembl chr16:31,201,486...31,203,450
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
kaempferol inhibits the reaction [Lipopolysaccharides affects the localization of and results in increased activity of RELA protein]; kaempferol inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]; kaempferol inhibits the reaction [TNF protein results in increased localization of RELA protein] kaempferol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of RELA protein] |
CTD |
PMID:16434028 PMID:18274639 PMID:20438634 PMID:30769083 |
|
NCBI chr11:65,653,601...65,662,946
Ensembl chr11:65,653,597...65,663,090
|
|
G |
RIPK1 |
receptor interacting serine/threonine kinase 1 |
multiple interactions |
ISO |
kaempferol inhibits the reaction [propacetamol results in increased expression of RIPK1 protein] |
CTD |
PMID:29574133 |
|
NCBI chr 6:3,063,967...3,115,187
Ensembl chr 6:3,063,991...3,115,187 Ensembl chr 6:3,063,991...3,115,187
|
|
G |
RPA3 |
replication protein A3 |
multiple interactions |
EXP |
[Vitamin E co-treated with Quercetin co-treated with kaempferol co-treated with 3,4-dihydroxyphenylethanol] results in increased expression of RPA3 mRNA |
CTD |
PMID:16797527 |
|
NCBI chr 7:7,636,518...7,718,607
Ensembl chr 7:7,636,518...7,718,607
|
|
G |
RUNX2 |
RUNX family transcription factor 2 |
increases expression |
ISO |
kaempferol results in increased expression of RUNX2 mRNA |
CTD |
PMID:23989061 |
|
NCBI chr 6:45,328,330...45,551,082
Ensembl chr 6:45,328,157...45,664,349
|
|
G |
SELE |
selectin E |
multiple interactions |
EXP |
kaempferol inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of SELE protein]; kaempferol inhibits the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:16987811 PMID:18394220 |
|
NCBI chr 1:169,722,640...169,734,079
Ensembl chr 1:169,722,640...169,764,705
|
|
G |
SFN |
stratifin |
increases expression |
EXP |
kaempferol results in increased expression of SFN mRNA; kaempferol results in increased expression of SFN protein |
CTD |
PMID:18331776 |
|
NCBI chr 1:26,863,149...26,864,456
Ensembl chr 1:26,863,149...26,864,456
|
|
G |
SLC16A1 |
solute carrier family 16 member 1 |
multiple interactions |
ISO EXP |
[kaempferol results in decreased activity of SLC16A1 protein] which results in decreased uptake of Sodium Oxybate kaempferol inhibits the reaction [SLC16A1 protein results in increased uptake of Lactic Acid] |
CTD |
PMID:17108059 PMID:25719685 |
|
NCBI chr 1:112,911,847...112,956,196
Ensembl chr 1:112,911,847...112,957,013
|
|
G |
SLC2A1 |
solute carrier family 2 member 1 |
decreases activity decreases expression multiple interactions |
EXP |
kaempferol results in decreased activity of SLC2A1 protein kaempferol results in decreased expression of SLC2A1 mRNA kaempferol inhibits the reaction [SLC2A1 protein affects the transport of Glucose] |
CTD |
PMID:14642735 PMID:25719685 |
|
NCBI chr 1:42,925,353...42,958,868
Ensembl chr 1:42,925,353...42,958,893 Ensembl chr 1:42,925,353...42,958,893
|
|
G |
SLC2A4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
kaempferol inhibits the reaction [INS1 protein affects the localization of SLC2A4 protein] |
CTD |
PMID:18591783 |
|
NCBI chr17:7,281,718...7,288,257
Ensembl chr17:7,281,718...7,288,257
|
|
G |
SLC5A8 |
solute carrier family 5 member 8 |
multiple interactions |
ISO |
kaempferol inhibits the reaction [Ethanol results in decreased expression of SLC5A8 protein] |
CTD |
PMID:31785310 |
|
NCBI chr12:101,155,493...101,210,238
Ensembl chr12:101,155,493...101,210,238
|
|
G |
SLCO1B1 |
solute carrier organic anion transporter family member 1B1 |
multiple interactions decreases activity |
EXP |
[kaempferol results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Fluvastatin; kaempferol inhibits the reaction [SLCO1B1 protein results in increased import of Atorvastatin]; kaempferol inhibits the reaction [SLCO1B1 protein results in increased import of Sulfobromophthalein] |
CTD |
PMID:22394605 PMID:32259555 |
|
NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
|
|
G |
SLCO1B3 |
solute carrier organic anion transporter family member 1B3 |
multiple interactions |
EXP |
kaempferol inhibits the reaction [SLCO1B3 protein results in increased import of Sulfobromophthalein] |
CTD |
PMID:22394605 |
|
NCBI chr12:20,810,705...20,916,911
Ensembl chr12:20,810,702...20,916,911
|
|
G |
SOD1 |
superoxide dismutase 1 |
multiple interactions increases expression |
EXP |
[pterostilbene co-treated with kaempferol] results in increased expression of SOD1 protein; [Quercetin co-treated with kaempferol] results in increased expression of SOD1 protein kaempferol results in increased expression of SOD1 protein |
CTD |
PMID:25111660 |
|
NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,622...31,668,931 Ensembl chr21:31,659,622...31,668,931
|
|
G |
SOD2 |
superoxide dismutase 2 |
multiple interactions affects response to substance increases expression |
ISO |
fulvestrant inhibits the reaction [kaempferol results in increased expression of SOD2 protein] SOD2 protein affects the susceptibility to kaempferol |
CTD |
PMID:23526725 |
|
NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529 Ensembl chr 6:159,669,069...159,762,529 Ensembl chr 6:159,669,069...159,762,529
|
|
G |
SOX9 |
SRY-box transcription factor 9 |
increases expression |
ISO |
kaempferol results in increased expression of SOX9 mRNA |
CTD |
PMID:23989061 |
|
NCBI chr17:72,121,020...72,126,416
Ensembl chr17:72,121,020...72,126,416
|
|
G |
SPP1 |
secreted phosphoprotein 1 |
multiple interactions |
ISO |
kaempferol inhibits the reaction [APOE affects the expression of SPP1 mRNA]; kaempferol inhibits the reaction [APOE affects the expression of SPP1 protein] |
CTD |
PMID:22005275 |
|
NCBI chr 4:87,975,714...87,983,411
Ensembl chr 4:87,975,650...87,983,426
|
|
G |
STAT1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
kaempferol inhibits the reaction [Lipopolysaccharides affects the localization of and results in increased activity of STAT1 protein alternative form] |
CTD |
PMID:18274639 |
|
NCBI chr 2:190,968,989...191,014,197
Ensembl chr 2:190,908,460...191,020,960 Ensembl chr 2:190,908,460...191,020,960
|
|
G |
STAT2 |
signal transducer and activator of transcription 2 |
multiple interactions |
EXP |
[Vitamin E co-treated with Quercetin co-treated with kaempferol co-treated with 3,4-dihydroxyphenylethanol] results in decreased expression of STAT2 mRNA |
CTD |
PMID:16797527 |
|
NCBI chr12:56,341,597...56,360,161
Ensembl chr12:56,341,597...56,360,167
|
|
G |
TFAM |
transcription factor A, mitochondrial |
increases expression |
EXP |
kaempferol results in increased expression of TFAM mRNA |
CTD |
PMID:17327447 |
|
NCBI chr10:58,385,409...58,399,220
Ensembl chr10:58,385,345...58,399,220
|
|
G |
TFF1 |
trefoil factor 1 |
increases expression multiple interactions |
EXP |
kaempferol results in increased expression of TFF1 mRNA ESR1 protein inhibits the reaction [kaempferol results in increased expression of TFF1 mRNA] |
CTD |
PMID:14706564 PMID:23384675 |
|
NCBI chr21:42,362,282...42,366,535
Ensembl chr21:42,362,282...42,366,535
|
|
G |
TGFA |
transforming growth factor alpha |
multiple interactions |
EXP |
kaempferol inhibits the reaction [TGFA protein results in increased expression of PTGS2 mRNA] |
CTD |
PMID:10783318 |
|
NCBI chr 2:70,447,284...70,553,826
Ensembl chr 2:70,447,284...70,554,193
|
|
G |
TJP1 |
tight junction protein 1 |
multiple interactions |
ISO |
kaempferol inhibits the reaction [Ethanol results in decreased expression of TJP1 protein] |
CTD |
PMID:31785310 |
|
NCBI chr15:29,699,367...29,969,049
Ensembl chr15:29,699,367...29,968,865 Ensembl chr15:29,699,367...29,968,865
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions decreases activity |
ISO EXP |
kaempferol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA]; kaempferol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; kaempferol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; kaempferol inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; kaempferol inhibits the reaction [propacetamol results in increased expression of TNF protein]; kaempferol inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; kaempferol inhibits the reaction [TNF protein results in increased localization of RELA protein]; kaempferol inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]; kaempferol inhibits the reaction [TNF protein results in increased secretion of IL6 protein] kaempferol results in decreased activity of TNF protein kaempferol inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of ICAM1 protein]; kaempferol inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; kaempferol inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of PTGS2 protein]; kaempferol inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of SELE protein]; kaempferol inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of VCAM1 protein]; kaempferol inhibits the reaction [IL32 protein results in increased expression of TNF mRNA]; kaempferol inhibits the reaction [IL32 protein results in increased secretion of TNF protein]; kaempferol inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; kaempferol inhibits the reaction [TNF protein results in increased activity of [FOS protein binds to JUN protein]]; kaempferol inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; kaempferol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; kaempferol inhibits the reaction [TNF protein results in increased expression of JUN mRNA]; kaempferol inhibits the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:15322261 PMID:15985724 PMID:16434028 PMID:16934226 PMID:16987811 PMID:18394220 PMID:20438634 PMID:28711657 PMID:29574133 PMID:30769083 PMID:31306686 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TNFAIP3 |
TNF alpha induced protein 3 |
multiple interactions |
EXP |
kaempferol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNFAIP3 mRNA] |
CTD |
PMID:20438634 |
|
NCBI chr 6:137,866,317...137,883,312
Ensembl chr 6:137,867,214...137,883,312
|
|
G |
TNFRSF11A |
TNF receptor superfamily member 11a |
multiple interactions |
ISO |
kaempferol inhibits the reaction [TNFSF11 protein results in increased expression of TNFRSF11A mRNA] |
CTD |
PMID:16434028 |
|
NCBI chr18:62,325,310...62,391,288
Ensembl chr18:62,325,287...62,391,288
|
|
G |
TNFSF11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
kaempferol inhibits the reaction [TNFSF11 protein results in increased expression of CALCR mRNA]; kaempferol inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; kaempferol inhibits the reaction [TNFSF11 protein results in increased expression of TNFRSF11A mRNA] |
CTD |
PMID:16434028 |
|
NCBI chr13:42,562,736...42,608,013
Ensembl chr13:42,562,736...42,608,013
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions affects response to substance increases phosphorylation increases expression |
EXP ISO |
Caffeine inhibits the reaction [kaempferol results in increased phosphorylation of TP53 protein]; TP53 protein affects the reaction [kaempferol promotes the reaction [BBC3 protein binds to BCL2L1 protein]] kaempferol inhibits the reaction [Doxorubicin promotes the reaction [TP53 protein binds to BAX promoter]]; kaempferol inhibits the reaction [Doxorubicin results in increased expression of TP53 mRNA] TP53 protein affects the susceptibility to kaempferol kaempferol results in increased expression of TP53 protein |
CTD |
PMID:19028473 PMID:22155320 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538 Ensembl chr17:7,661,779...7,687,538
|
|
G |
TP53I3 |
tumor protein p53 inducible protein 3 |
increases expression |
EXP |
kaempferol results in increased expression of TP53I3 mRNA; kaempferol results in increased expression of TP53I3 protein |
CTD |
PMID:18331776 PMID:19397994 |
|
NCBI chr 2:24,077,428...24,085,767
Ensembl chr 2:24,077,433...24,085,861
|
|
G |
TP63 |
tumor protein p63 |
increases expression |
EXP |
kaempferol results in increased expression of TP63 protein |
CTD |
PMID:18331776 PMID:19397994 |
|
NCBI chr 3:189,596,746...189,897,276
Ensembl chr 3:189,631,389...189,897,276
|
|
G |
TP73 |
tumor protein p73 |
increases expression |
EXP |
kaempferol results in increased expression of TP73 protein |
CTD |
PMID:18331776 PMID:19397994 |
|
NCBI chr 1:3,652,516...3,736,201
Ensembl chr 1:3,652,516...3,736,201
|
|
G |
TRAF6 |
TNF receptor associated factor 6 |
multiple interactions |
EXP |
kaempferol inhibits the reaction [IL1B protein results in increased ubiquitination of TRAF6 protein] |
CTD |
PMID:30769083 |
|
NCBI chr11:36,483,769...36,510,313
Ensembl chr11:36,483,769...36,510,272
|
|
G |
TSLP |
thymic stromal lymphopoietin |
multiple interactions |
EXP |
kaempferol inhibits the reaction [IL32 protein results in increased expression of TSLP mRNA]; kaempferol inhibits the reaction [IL32 protein results in increased secretion of TSLP protein]; kaempferol inhibits the reaction [Lipopolysaccharides results in increased secretion of TSLP protein] |
CTD |
PMID:28711657 |
|
NCBI chr 5:111,070,062...111,078,026
Ensembl chr 5:111,070,062...111,078,026
|
|
G |
TUBB3 |
tubulin beta 3 class III |
decreases expression |
ISO |
kaempferol results in decreased expression of TUBB3 protein |
CTD |
PMID:26683311 |
|
NCBI chr16:89,921,925...89,936,097
Ensembl chr16:89,921,392...89,938,761
|
|
G |
UCP1 |
uncoupling protein 1 |
multiple interactions |
ISO |
kaempferol inhibits the reaction [Dietary Fats results in decreased expression of UCP1 mRNA] |
CTD |
PMID:30372826 |
|
NCBI chr 4:140,555,770...140,568,961
Ensembl chr 4:140,559,431...140,568,961
|
|
G |
UCP3 |
uncoupling protein 3 |
increases expression |
EXP |
kaempferol results in increased expression of UCP3 mRNA |
CTD |
PMID:17327447 |
|
NCBI chr11:74,000,277...74,009,085
Ensembl chr11:74,000,277...74,009,085
|
|
G |
UGT1A1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation multiple interactions |
EXP ISO |
UGT1A1 protein results in increased glucuronidation of kaempferol kaempferol inhibits the reaction [propacetamol results in decreased expression of UGT1A1 protein] |
CTD |
PMID:14557274 PMID:29574133 |
|
NCBI chr 2:233,760,270...233,773,300
Ensembl chr 2:233,760,270...233,773,300 Ensembl chr 2:233,760,270...233,773,300
|
|
G |
UGT1A10 |
UDP glucuronosyltransferase family 1 member A10 |
increases glucuronidation |
EXP |
UGT1A10 protein results in increased glucuronidation of kaempferol |
CTD |
PMID:14557274 |
|
NCBI chr 2:233,636,477...233,773,305
Ensembl chr 2:233,636,454...233,773,305
|
|
G |
UGT1A3 |
UDP glucuronosyltransferase family 1 member A3 |
affects glucuronidation increases glucuronidation |
EXP |
UGT1A3 mutant form affects the glucuronidation of kaempferol UGT1A3 protein results in increased glucuronidation of kaempferol |
CTD |
PMID:16738032 |
|
NCBI chr 2:233,729,042...233,773,300
Ensembl chr 2:233,729,108...233,773,299
|
|
G |
UGT1A7 |
UDP glucuronosyltransferase family 1 member A7 |
increases glucuronidation |
EXP |
UGT1A7 protein results in increased glucuronidation of kaempferol |
CTD |
PMID:14557274 |
|
NCBI chr 2:233,681,901...233,773,300
Ensembl chr 2:233,681,938...233,773,299
|
|
G |
UGT1A8 |
UDP glucuronosyltransferase family 1 member A8 |
increases glucuronidation |
EXP |
UGT1A8 protein results in increased glucuronidation of kaempferol |
CTD |
PMID:14557274 |
|
NCBI chr 2:233,617,633...233,773,300
Ensembl chr 2:233,617,645...233,773,310
|
|
G |
UGT1A9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation |
EXP |
UGT1A9 protein results in increased glucuronidation of kaempferol |
CTD |
PMID:14557274 |
|
NCBI chr 2:233,671,898...233,773,300
Ensembl chr 2:233,671,898...233,773,300
|
|
G |
UTRN |
utrophin |
increases expression |
EXP |
kaempferol results in increased expression of UTRN mRNA |
CTD |
PMID:22028826 |
|
NCBI chr 6:144,284,955...144,853,034
Ensembl chr 6:144,285,701...144,853,034
|
|
G |
VCAM1 |
vascular cell adhesion molecule 1 |
multiple interactions |
EXP |
kaempferol inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of VCAM1 protein] |
CTD |
PMID:18394220 |
|
NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045
|
|
G |
VDR |
vitamin D receptor |
increases activity |
EXP |
kaempferol results in increased activity of VDR protein |
CTD |
PMID:26366751 |
|
NCBI chr12:47,841,537...47,905,022
Ensembl chr12:47,841,537...47,943,048
|
|
G |
VEGFA |
vascular endothelial growth factor A |
multiple interactions |
EXP |
kaempferol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of VEGFA mRNA] |
CTD |
PMID:20438634 |
|
NCBI chr 6:43,770,209...43,786,487
Ensembl chr 6:43,770,184...43,786,487
|
|
|
G |
PLA2G2A |
phospholipase A2 group IIA |
affects activity |
EXP |
kaempferol-3-O-galactoside affects the activity of PLA2G2A protein |
CTD |
PMID:8190018 |
|
NCBI chr 1:19,975,431...19,980,434
Ensembl chr 1:19,975,431...19,980,416
|
|
|
G |
CCL2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA] |
CTD |
PMID:22210036 |
|
NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,218...34,257,203
|
|
G |
CCL3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA] |
CTD |
PMID:22210036 |
|
NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
ISO |
astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] |
CTD |
PMID:22210036 |
|
NCBI chr 2:112,829,751...112,836,843
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
ISO |
astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:22210036 |
|
NCBI chr 7:22,725,889...22,732,002
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
multiple interactions |
ISO |
astragalin inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein] |
CTD |
PMID:22210036 |
|
NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,511...35,404,749 Ensembl chr14:35,401,511...35,404,749
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:22210036 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] |
CTD |
PMID:22210036 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,423
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
astragalin inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein] |
CTD |
PMID:22210036 |
|
NCBI chr11:65,653,601...65,662,946
Ensembl chr11:65,653,597...65,663,090
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
ISO |
astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:22210036 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
multiple interactions increases expression |
ISO |
geranylgeranyl pyrophosphate inhibits the reaction [kuwanon G results in increased expression of ABCB1 protein] kuwanon G results in increased expression of ABCB1 mRNA; kuwanon G results in increased expression of ABCB1 protein |
CTD |
PMID:29355567 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323 Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ABCG1 |
ATP binding cassette subfamily G member 1 |
multiple interactions increases expression |
ISO |
geranylgeranyl pyrophosphate inhibits the reaction [kuwanon G results in increased expression of ABCG1 protein] kuwanon G results in increased expression of ABCG1 mRNA; kuwanon G results in increased expression of ABCG1 protein |
CTD |
PMID:29355567 |
|
NCBI chr21:42,199,689...42,304,387
Ensembl chr21:42,199,689...42,297,244
|
|
G |
APOE |
apolipoprotein E |
multiple interactions |
ISO |
kuwanon G inhibits the reaction [[APOE gene mutant form results in increased susceptibility to Dietary Fats] which results in increased expression of and results in increased secretion of IFNG protein]; kuwanon G inhibits the reaction [[APOE gene mutant form results in increased susceptibility to Dietary Fats] which results in increased expression of and results in increased secretion of IL1B protein]; kuwanon G inhibits the reaction [[APOE gene mutant form results in increased susceptibility to Dietary Fats] which results in increased expression of and results in increased secretion of IL6 protein]; kuwanon G inhibits the reaction [[APOE gene mutant form results in increased susceptibility to Dietary Fats] which results in increased expression of and results in increased secretion of TNF protein]; kuwanon G inhibits the reaction [[APOE gene mutant form results in increased susceptibility to Dietary Fats] which results in increased uptake of Lipids] |
CTD |
PMID:29355567 |
|
NCBI chr19:44,905,796...44,909,393
Ensembl chr19:44,905,791...44,909,393
|
|
G |
GRP |
gastrin releasing peptide |
multiple interactions |
ISO |
kuwanon G inhibits the reaction [GRP protein binds to GRPR protein] |
CTD |
PMID:7646517 |
|
NCBI chr18:59,219,188...59,230,771
Ensembl chr18:59,220,158...59,230,774
|
|
G |
GRPR |
gastrin releasing peptide receptor |
multiple interactions |
ISO |
kuwanon G binds to and results in decreased activity of GRPR protein; kuwanon G inhibits the reaction [GRP protein binds to GRPR protein] |
CTD |
PMID:7646517 |
|
NCBI chr X:16,123,565...16,153,518
Ensembl chr X:16,123,565...16,153,518
|
|
G |
IFNG |
interferon gamma |
multiple interactions |
ISO |
kuwanon G inhibits the reaction [[APOE gene mutant form results in increased susceptibility to Dietary Fats] which results in increased expression of and results in increased secretion of IFNG protein]; kuwanon G inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of IFNG mRNA] |
CTD |
PMID:29355567 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
ISO |
kuwanon G inhibits the reaction [[APOE gene mutant form results in increased susceptibility to Dietary Fats] which results in increased expression of and results in increased secretion of IL1B protein]; kuwanon G inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of IL1B mRNA] |
CTD |
PMID:29355567 |
|
NCBI chr 2:112,829,751...112,836,843
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
ISO |
kuwanon G inhibits the reaction [[APOE gene mutant form results in increased susceptibility to Dietary Fats] which results in increased expression of and results in increased secretion of IL6 protein]; kuwanon G inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of IL6 mRNA] |
CTD |
PMID:29355567 |
|
NCBI chr 7:22,725,889...22,732,002
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
multiple interactions |
ISO |
kuwanon G inhibits the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of NFKBIA protein] |
CTD |
PMID:29355567 |
|
NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,511...35,404,749 Ensembl chr14:35,401,511...35,404,749
|
|
G |
NR1H3 |
nuclear receptor subfamily 1 group H member 3 |
increases expression |
ISO |
kuwanon G results in increased expression of NR1H3 protein |
CTD |
PMID:29355567 |
|
NCBI chr11:47,248,300...47,269,033
Ensembl chr11:47,248,300...47,269,033
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
kuwanon G inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of RELA protein] |
CTD |
PMID:29355567 |
|
NCBI chr11:65,653,601...65,662,946
Ensembl chr11:65,653,597...65,663,090
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
ISO |
kuwanon G inhibits the reaction [[APOE gene mutant form results in increased susceptibility to Dietary Fats] which results in increased expression of and results in increased secretion of TNF protein]; kuwanon G inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of TNF mRNA] |
CTD |
PMID:29355567 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
|
G |
GRP |
gastrin releasing peptide |
multiple interactions |
ISO |
kuwanon H inhibits the reaction [GRP protein binds to NMBR protein] kuwanon H inhibits the reaction [GRP protein binds to GRPR protein] |
CTD |
PMID:7646517 |
|
NCBI chr18:59,219,188...59,230,771
Ensembl chr18:59,220,158...59,230,774
|
|
G |
GRPR |
gastrin releasing peptide receptor |
multiple interactions |
ISO |
kuwanon H binds to and results in decreased activity of GRPR protein; kuwanon H inhibits the reaction [GRP protein binds to GRPR protein] |
CTD |
PMID:7646517 |
|
NCBI chr X:16,123,565...16,153,518
Ensembl chr X:16,123,565...16,153,518
|
|
G |
NMBR |
neuromedin B receptor |
multiple interactions |
ISO |
kuwanon H inhibits the reaction [GRP protein binds to NMBR protein] |
CTD |
PMID:7646517 |
|
NCBI chr 6:142,074,484...142,147,122
Ensembl chr 6:142,058,330...142,088,799
|
|
|
G |
ABCC1 |
ATP binding cassette subfamily C member 1 |
decreases activity |
EXP |
Luteolin results in decreased activity of ABCC1 protein |
CTD |
PMID:15670588 |
|
NCBI chr16:15,949,616...16,143,062
Ensembl chr16:15,949,577...16,143,074 Ensembl chr16:15,949,577...16,143,074
|
|
G |
ABCC2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[Luteolin co-treated with Cisplatin] results in increased expression of ABCC2 protein; Luteolin inhibits the reaction [Cisplatin results in increased expression of ABCC2 protein] |
CTD |
PMID:23770416 |
|
NCBI chr10:99,782,602...99,853,741
Ensembl chr10:99,782,640...99,852,594
|
|
G |
ABCC4 |
ATP binding cassette subfamily C member 4 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Cisplatin results in increased expression of ABCC4 protein] |
CTD |
PMID:23770416 |
|
NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475
|
|
G |
ABCG2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
affects activity |
EXP |
Luteolin affects the activity of ABCG2 protein |
CTD |
PMID:20403331 |
|
NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628
|
|
G |
ACHE |
acetylcholinesterase (Cartwright blood group) |
multiple interactions |
ISO |
Luteolin inhibits the reaction [cobaltous chloride results in increased activity of ACHE protein] |
CTD |
PMID:31362009 |
|
NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974
|
|
G |
ACTA2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] |
CTD |
PMID:19747501 |
|
NCBI chr10:88,935,074...88,991,397
Ensembl chr10:88,935,074...88,991,339
|
|
G |
AGER |
advanced glycosylation end-product specific receptor |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Glucose results in increased expression of AGER mRNA] |
CTD |
PMID:19557821 |
|
NCBI chr 6:32,180,969...32,184,380
Ensembl chr 6:32,180,968...32,184,322
|
|
G |
AHR |
aryl hydrocarbon receptor |
multiple interactions |
EXP ISO |
Luteolin binds to and results in decreased activity of AHR protein Luteolin inhibits the reaction [Tetrachlorodibenzodioxin results in increased localization of AHR protein] |
CTD |
PMID:14644660 PMID:20450880 |
|
NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation increases phosphorylation decreases expression |
EXP ISO |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of AKT1 protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Luteolin inhibits the reaction [Oxygen deficiency results in increased phosphorylation of AKT1 protein] Luteolin results in decreased phosphorylation of AKT1 protein Luteolin results in increased phosphorylation of AKT1 protein Luteolin inhibits the reaction [Antimycin A results in decreased activity of AKT1 protein]; Luteolin inhibits the reaction [INS1 protein results in increased activity of AKT1 protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein] [Luteolin co-treated with Hydrogen Peroxide] results in increased expression of AKT1 protein; Luteolin inhibits the reaction [lipoteichoic acid results in increased phosphorylation of AKT1 protein]; Luteolin inhibits the reaction [Methamphetamine results in increased phosphorylation of AKT1 protein] Luteolin results in decreased expression of AKT1 protein |
CTD |
PMID:18591783 PMID:18720166 PMID:19344998 PMID:20153296 PMID:20685402 PMID:21782929 PMID:22926442 PMID:25448439 PMID:27474067 PMID:27525270 PMID:32035215 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
|
|
G |
ALOX5 |
arachidonate 5-lipoxygenase |
multiple interactions |
EXP |
Luteolin inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4] |
CTD |
PMID:18096136 |
|
NCBI chr10:45,374,209...45,446,121
Ensembl chr10:45,374,176...45,446,119
|
|
G |
ASNS |
asparagine synthetase (glutamine-hydrolyzing) |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Tunicamycin results in increased expression of ASNS mRNA] |
CTD |
PMID:32407927 |
|
NCBI chr 7:97,851,677...97,928,441
Ensembl chr 7:97,851,677...97,872,542
|
|
G |
ATF6 |
activating transcription factor 6 |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Thapsigargin results in increased expression of ATF6 protein modified form]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of ATF6 protein modified form] |
CTD |
PMID:32407927 |
|
NCBI chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,320...161,964,070
|
|
G |
ATG5 |
autophagy related 5 |
multiple interactions increases expression |
ISO EXP |
Luteolin inhibits the reaction [Methamphetamine results in increased expression of ATG5 protein] Luteolin results in increased expression of ATG5 protein |
CTD |
PMID:32035215 PMID:32268164 |
|
NCBI chr 6:106,184,476...106,325,789
Ensembl chr 6:106,045,423...106,325,791
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
Luteolin inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX protein]; Luteolin inhibits the reaction [Methamphetamine results in increased expression of BAX protein] Luteolin results in increased expression of BAX protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in increased expression of BAX protein] |
CTD |
PMID:21601631 PMID:27474067 PMID:27525270 PMID:32035215 PMID:32268164 |
|
NCBI chr19:48,954,825...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions decreases expression |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in decreased expression of BCL2 protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of BCL2 protein]; Luteolin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of BCL2 protein] |
CTD |
PMID:19557821 PMID:25448439 PMID:27474067 PMID:32268164 |
|
NCBI chr18:63,123,346...63,320,280
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BCL2L1 |
BCL2 like 1 |
decreases expression multiple interactions |
EXP |
Luteolin results in decreased expression of BCL2L1 protein Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of BCL2L1 protein] |
CTD |
PMID:21601631 PMID:25448439 |
|
NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
|
|
G |
BECN1 |
beclin 1 |
multiple interactions increases expression |
ISO EXP |
Luteolin inhibits the reaction [Methamphetamine results in increased expression of BECN1 protein] Luteolin results in increased expression of BECN1 protein |
CTD |
PMID:32035215 PMID:32268164 |
|
NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350
|
|
G |
BIRC2 |
baculoviral IAP repeat containing 2 |
multiple interactions |
EXP |
Luteolin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein] |
CTD |
PMID:15334063 |
|
NCBI chr11:102,347,214...102,378,670
Ensembl chr11:102,347,211...102,378,670
|
|
G |
CASP1 |
caspase 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Freund's Adjuvant results in increased cleavage of CASP1 protein] |
CTD |
PMID:25450234 |
|
NCBI chr11:105,025,443...105,035,591
Ensembl chr11:105,025,443...105,035,250
|
|
G |
CASP3 |
caspase 3 |
multiple interactions increases expression increases cleavage increases activity |
EXP ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in increased cleavage of CASP3 protein]; [Luteolin co-treated with Paclitaxel] results in increased cleavage of CASP3 protein; Luteolin promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Luteolin results in increased expression of and results in increased cleavage of CASP3 protein Luteolin results in increased expression of CASP3 protein Luteolin inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]; Luteolin inhibits the reaction [Methamphetamine results in increased cleavage of CASP3 protein] Luteolin results in increased activity of CASP3 protein Luteolin inhibits the reaction [Cisplatin results in increased cleavage of and results in increased expression of CASP3 protein]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of CASP3 protein modified form] |
CTD |
PMID:16140950 PMID:18331776 PMID:19397994 PMID:21074525 PMID:21601631 PMID:23770416 PMID:24525192 PMID:27474067 PMID:27489195 PMID:27525270 PMID:31288002 PMID:32035215 PMID:32268164 PMID:32407927 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
|
|
G |
CASP7 |
caspase 7 |
increases activity |
EXP |
Luteolin results in increased activity of CASP7 protein |
CTD |
PMID:21074525 |
|
NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907
|
|
G |
CASP8 |
caspase 8 |
multiple interactions |
EXP ISO |
[Luteolin co-treated with Paclitaxel] results in increased cleavage of CASP8 protein; Luteolin promotes the reaction [TNF protein results in increased cleavage of and results in increased activity of CASP8 protein]; Luteolin promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein] Luteolin inhibits the reaction [Hydrogen Peroxide results in increased expression of CASP8 protein] |
CTD |
PMID:15334063 PMID:16140950 PMID:24525192 PMID:27525270 |
|
NCBI chr 2:201,233,443...201,287,711
Ensembl chr 2:201,233,443...201,287,711
|
|
G |
CASP9 |
caspase 9 |
increases activity increases cleavage |
EXP |
Luteolin results in increased activity of CASP9 protein Luteolin results in increased cleavage of CASP9 protein |
CTD |
PMID:18331776 PMID:19397994 PMID:21601631 PMID:27474067 PMID:27489195 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
affects activity decreases activity multiple interactions |
EXP ISO |
Luteolin affects the activity of CAT protein Luteolin results in decreased activity of CAT protein Fluorouracil promotes the reaction [Luteolin results in decreased activity of CAT protein]; Luteolin inhibits the reaction [Doxorubicin results in increased activity of CAT protein]; Luteolin promotes the reaction [Fluorouracil results in decreased activity of CAT protein] |
CTD |
PMID:18503759 PMID:31288002 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCL2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
Luteolin inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein] |
CTD |
PMID:24134915 |
|
NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,218...34,257,203
|
|
G |
CCN5 |
cellular communication network factor 5 |
decreases expression |
EXP |
Luteolin results in decreased expression of CCN5 mRNA |
CTD |
PMID:19397994 |
|
NCBI chr20:44,714,204...44,728,041
Ensembl chr20:44,714,844...44,728,509
|
|
G |
CCNA2 |
cyclin A2 |
decreases expression |
EXP |
Luteolin results in decreased expression of CCNA2 protein |
CTD |
PMID:22926442 |
|
NCBI chr 4:121,816,444...121,823,883
Ensembl chr 4:121,816,444...121,823,883 Ensembl chr 4:121,816,444...121,823,883
|
|
G |
CCNB1 |
cyclin B1 |
decreases expression |
EXP |
Luteolin results in decreased expression of CCNB1 mRNA; Luteolin results in decreased expression of CCNB1 protein |
CTD |
PMID:18331776 PMID:19397994 PMID:22926442 |
|
NCBI chr 5:69,167,150...69,178,245
Ensembl chr 5:69,167,135...69,178,245
|
|
G |
CCND1 |
cyclin D1 |
multiple interactions decreases expression |
ISO |
Fluorouracil promotes the reaction [Luteolin results in decreased expression of CCND1 protein]; Luteolin promotes the reaction [Fluorouracil results in decreased expression of CCND1 protein] |
CTD |
PMID:31288002 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474 Ensembl chr11:69,641,156...69,654,474
|
|
G |
CD40 |
CD40 molecule |
multiple interactions |
EXP |
Luteolin inhibits the reaction [[Calcimycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CD40 protein]; Luteolin inhibits the reaction [Calcimycin results in increased expression of CD40 protein]; Luteolin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CD40 protein] |
CTD |
PMID:16601352 |
|
NCBI chr20:46,118,242...46,129,858
Ensembl chr20:46,118,278...46,129,863
|
|
G |
CD74 |
CD74 molecule |
decreases expression |
EXP |
Luteolin results in decreased expression of CD74 mRNA |
CTD |
PMID:18818744 |
|
NCBI chr 5:150,400,041...150,412,936
Ensembl chr 5:150,400,041...150,412,929
|
|
G |
CDH1 |
cadherin 1 |
multiple interactions increases expression |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in increased expression of CDH1 protein] |
CTD |
PMID:27474067 PMID:32268164 |
|
NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,541
|
|
G |
CDH2 |
cadherin 2 |
multiple interactions decreases expression |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in decreased expression of CDH2 protein] |
CTD |
PMID:27474067 |
|
NCBI chr18:27,932,878...28,177,130
Ensembl chr18:27,932,879...28,177,946 Ensembl chr18:27,932,879...28,177,946
|
|
G |
CDH5 |
cadherin 5 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Methamphetamine results in increased expression of CDH5 mRNA] |
CTD |
PMID:32035215 |
|
NCBI chr16:66,366,657...66,404,784
Ensembl chr16:66,366,622...66,404,784
|
|
G |
CDK1 |
cyclin dependent kinase 1 |
decreases expression |
EXP |
Luteolin results in decreased expression of CDK1 protein |
CTD |
PMID:22926442 |
|
NCBI chr10:60,778,331...60,794,852
Ensembl chr10:60,778,331...60,794,852
|
|
G |
CDK2 |
cyclin dependent kinase 2 |
decreases activity decreases expression |
EXP |
Luteolin results in decreased activity of CDK2 protein Luteolin results in decreased expression of CDK2 protein |
CTD |
PMID:11322924 PMID:22926442 |
|
NCBI chr12:55,966,830...55,972,789
Ensembl chr12:55,966,781...55,972,789
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
increases expression multiple interactions |
EXP ISO |
Luteolin results in increased expression of CDKN1A mRNA; Luteolin results in increased expression of CDKN1A protein Fluorouracil promotes the reaction [Luteolin results in increased expression of CDKN1A protein]; Luteolin promotes the reaction [Fluorouracil results in increased expression of CDKN1A protein] |
CTD |
PMID:11322924 PMID:11790449 PMID:19397994 PMID:22926442 PMID:31288002 PMID:32268164 |
|
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,339 Ensembl chr 6:36,676,460...36,687,339
|
|
G |
CDKN1B |
cyclin dependent kinase inhibitor 1B |
increases expression |
EXP |
Luteolin results in increased expression of CDKN1B protein |
CTD |
PMID:11322924 |
|
NCBI chr12:12,717,368...12,722,369
Ensembl chr12:12,715,058...12,722,369
|
|
G |
CDKN2C |
cyclin dependent kinase inhibitor 2C |
decreases expression |
EXP |
Luteolin results in decreased expression of CDKN2C mRNA |
CTD |
PMID:18331776 |
|
NCBI chr 1:50,968,706...50,974,634
Ensembl chr 1:50,960,745...50,974,634
|
|
G |
CHUK |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
EXP |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased activity of CHUK protein] |
CTD |
PMID:25448439 |
|
NCBI chr10:100,188,300...100,229,610
Ensembl chr10:100,188,300...100,229,596
|
|
G |
CSF2 |
colony stimulating factor 2 |
decreases expression multiple interactions |
EXP ISO |
Luteolin results in decreased expression of CSF2 mRNA Luteolin inhibits the reaction [Calcimycin results in increased expression of CSF2 mRNA] |
CTD |
PMID:10718847 PMID:17950587 |
|
NCBI chr 5:132,073,789...132,076,170
Ensembl chr 5:132,073,789...132,076,170
|
|
G |
CTNNB1 |
catenin beta 1 |
decreases expression |
EXP |
Luteolin results in decreased expression of CTNNB1 protein |
CTD |
PMID:32268164 |
|
NCBI chr 3:41,199,422...41,240,445
Ensembl chr 3:41,194,741...41,260,096
|
|
G |
CXCL10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA] |
CTD |
PMID:19426678 |
|
NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497
|
|
G |
CXCL12 |
C-X-C motif chemokine ligand 12 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Methamphetamine results in increased expression of CXCL12 mRNA] |
CTD |
PMID:32035215 |
|
NCBI chr10:44,292,088...44,385,097
Ensembl chr10:44,370,165...44,386,493
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions |
EXP |
Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CXCL8 mRNA]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased secretion of CXCL8 protein] |
CTD |
PMID:25448439 PMID:30133131 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,541...73,743,716
|
|
G |
CXCL9 |
C-X-C motif chemokine ligand 9 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL9 mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of CXCL9 mRNA] |
CTD |
PMID:19426678 |
|
NCBI chr 4:76,001,275...76,007,509
Ensembl chr 4:76,001,275...76,007,509
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
multiple interactions increases expression decreases activity |
EXP ISO |
Luteolin inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; Luteolin inhibits the reaction [Dust analog results in increased expression of CYP1A1 mRNA]; Luteolin inhibits the reaction [Particulate Matter analog results in increased expression of CYP1A1 mRNA]; Luteolin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Luteolin inhibits the reaction [Vehicle Emissions analog results in increased expression of CYP1A1 mRNA] Luteolin results in increased expression of CYP1A1 mRNA Luteolin affects the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA] Luteolin results in decreased activity of CYP1A1 protein |
CTD |
PMID:16263508 PMID:17090139 PMID:20403331 PMID:20930378 PMID:21482471 PMID:23994263 PMID:29584932 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
decreases activity |
EXP |
Luteolin results in decreased activity of CYP1A2 protein |
CTD |
PMID:29753067 |
|
NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
decreases activity increases expression |
EXP |
Luteolin results in decreased activity of CYP1B1 protein Luteolin results in increased expression of CYP1B1 mRNA |
CTD |
PMID:21482471 PMID:23994263 |
|
NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902
|
|
G |
CYP2C19 |
cytochrome P450 family 2 subfamily C member 19 |
decreases activity |
EXP |
Luteolin results in decreased activity of CYP2C19 protein |
CTD |
PMID:29753067 |
|
NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547
|
|
G |
CYP2C9 |
cytochrome P450 family 2 subfamily C member 9 |
decreases activity |
EXP |
Luteolin results in decreased activity of CYP2C9 protein |
CTD |
PMID:29753067 |
|
NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Cisplatin results in increased expression of CYP2E1 protein] |
CTD |
PMID:23770416 |
|
NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
multiple interactions |
EXP |
Luteolin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Luteolin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam] |
CTD |
PMID:18191104 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
CYP3A5 |
cytochrome P450 family 3 subfamily A member 5 |
multiple interactions |
EXP |
Luteolin inhibits the reaction [CYP3A5 protein results in increased chemical synthesis of 4-hydroxymidazolam] |
CTD |
PMID:18191104 |
|
NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,998
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
multiple interactions |
ISO EXP |
Luteolin inhibits the reaction [Thapsigargin results in increased expression of DDIT3 protein]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein] Luteolin inhibits the reaction [Thapsigargin results in increased expression of DDIT3 mRNA]; Luteolin inhibits the reaction [Thapsigargin results in increased expression of DDIT3 protein]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein]; SESN2 protein promotes the reaction [Luteolin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]] |
CTD |
PMID:32407927 |
|
NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
|
|
G |
DHRS11 |
dehydrogenase/reductase 11 |
decreases activity |
EXP |
Luteolin results in decreased activity of DHRS11 protein |
CTD |
PMID:30926317 |
|
NCBI chr17:36,591,846...36,600,804
Ensembl chr17:36,591,879...36,600,804
|
|
G |
DNAJB9 |
DnaJ heat shock protein family (Hsp40) member B9 |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Tunicamycin results in increased expression of DNAJB9 mRNA] |
CTD |
PMID:32407927 |
|
NCBI chr 7:108,569,874...108,574,850
Ensembl chr 7:108,569,867...108,574,850
|
|
G |
DRAM1 |
DNA damage regulated autophagy modulator 1 |
increases expression multiple interactions |
ISO |
Luteolin results in increased expression of DRAM1 protein Fluorouracil promotes the reaction [Luteolin results in increased expression of DRAM1 protein]; Luteolin promotes the reaction [Fluorouracil results in increased expression of DRAM1 protein] |
CTD |
PMID:31288002 |
|
NCBI chr12:101,877,327...101,923,623
Ensembl chr12:101,877,580...102,012,130
|
|
G |
EGF |
epidermal growth factor |
multiple interactions |
EXP |
EGF protein inhibits the reaction [Luteolin results in decreased phosphorylation of EGFR protein]; EGF protein inhibits the reaction [Luteolin results in decreased phosphorylation of PTK2 protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of PTK2 protein]; Luteolin inhibits the reaction [EGF protein results in increased secretion of MMP9 protein] |
CTD |
PMID:10556937 PMID:12168845 PMID:15135307 PMID:22926442 |
|
NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766
|
|
G |
EGFR |
epidermal growth factor receptor |
decreases expression multiple interactions affects response to substance |
EXP |
Luteolin results in decreased expression of EGFR mRNA EGF protein inhibits the reaction [Luteolin results in decreased phosphorylation of EGFR protein]; Luteolin affects the activity of and results in decreased phosphorylation of EGFR protein; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Luteolin results in decreased phosphorylation of and results in increased activity of EGFR protein EGFR protein affects the susceptibility to Luteolin |
CTD |
PMID:10556937 PMID:12168845 PMID:15135307 PMID:22926442 |
|
NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628
|
|
G |
EGR1 |
early growth response 1 |
increases expression |
EXP |
Luteolin results in increased expression of EGR1 mRNA |
CTD |
PMID:19397994 |
|
NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303
|
|
G |
EIF2S1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Thapsigargin results in increased phosphorylation of EIF2S1 protein]; Luteolin inhibits the reaction [Tunicamycin results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:32407927 |
|
NCBI chr14:67,360,328...67,386,516
Ensembl chr14:67,360,151...67,386,516 Ensembl chr14:67,360,151...67,386,516
|
|
G |
ERN1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Thapsigargin results in increased expression of and results in increased phosphorylation of ERN1 protein]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of and results in increased phosphorylation of ERN1 protein] |
CTD |
PMID:32407927 |
|
NCBI chr17:64,039,142...64,132,469
Ensembl chr17:64,039,142...64,130,819
|
|
G |
ESR1 |
estrogen receptor 1 |
affects binding multiple interactions |
EXP |
Luteolin binds to ESR1 protein Luteolin inhibits the reaction [Estradiol binds to ESR1 protein] |
CTD |
PMID:14579009 |
|
NCBI chr 6:151,654,148...152,129,619
Ensembl chr 6:151,656,691...152,129,619
|
|
G |
ESR2 |
estrogen receptor 2 |
increases activity affects binding |
EXP |
Luteolin results in increased activity of ESR2 protein Luteolin binds to ESR2 protein |
CTD |
PMID:12224631 PMID:16860978 |
|
NCBI chr14:64,226,707...64,338,631
Ensembl chr14:64,084,232...64,338,112
|
|
G |
F11R |
F11 receptor |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Methamphetamine results in increased expression of F11R mRNA] |
CTD |
PMID:32035215 |
|
NCBI chr 1:160,995,211...161,021,152
Ensembl chr 1:160,995,211...161,021,343
|
|
G |
FASN |
fatty acid synthase |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Tunicamycin results in increased expression of FASN mRNA] |
CTD |
PMID:32407927 |
|
NCBI chr17:82,078,338...82,098,303
Ensembl chr17:82,078,338...82,098,294
|
|
G |
FBP1 |
fructose-bisphosphatase 1 |
decreases expression |
EXP |
Luteolin results in decreased expression of FBP1 mRNA |
CTD |
PMID:18331776 |
|
NCBI chr 9:94,603,133...94,640,263
Ensembl chr 9:94,603,133...94,640,249
|
|
G |
FGF2 |
fibroblast growth factor 2 |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA] |
CTD |
PMID:26800359 |
|
NCBI chr 4:122,826,708...122,898,236
Ensembl chr 4:122,826,708...122,898,236
|
|
G |
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases activity |
EXP ISO |
Luteolin inhibits the reaction [TNF protein results in increased activity of [FOS protein binds to JUN protein]]; Luteolin inhibits the reaction [TNF protein results in increased expression of FOS mRNA] Luteolin inhibits the reaction [Calcimycin results in increased expression of FOS mRNA] Luteolin results in decreased activity of FOS protein |
CTD |
PMID:15322261 PMID:16343431 PMID:17950587 |
|
NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230
|
|
G |
FOSB |
FosB proto-oncogene, AP-1 transcription factor subunit |
decreases activity |
EXP |
Luteolin results in decreased activity of FOSB protein |
CTD |
PMID:16343431 |
|
NCBI chr19:45,467,996...45,475,179
Ensembl chr19:45,467,995...45,475,179
|
|
G |
FOXO3 |
forkhead box O3 |
multiple interactions |
EXP |
Luteolin results in increased expression of and results in increased phosphorylation of FOXO3 protein; PD 0325901 inhibits the reaction [Luteolin results in increased phosphorylation of FOXO3 protein]; PD 0325901 promotes the reaction [Luteolin results in increased expression of FOXO3 protein] |
CTD |
PMID:32268164 |
|
NCBI chr 6:108,559,825...108,684,774
Ensembl chr 6:108,559,835...108,684,774
|
|
G |
GADD45B |
growth arrest and DNA damage inducible beta |
increases expression |
EXP |
Luteolin results in increased expression of GADD45B mRNA; Luteolin results in increased expression of GADD45B protein |
CTD |
PMID:18331776 |
|
NCBI chr19:2,476,127...2,478,259
Ensembl chr19:2,476,122...2,478,259
|
|
G |
GCLC |
glutamate-cysteine ligase catalytic subunit |
increases expression multiple interactions |
ISO |
Luteolin results in increased expression of GCLC mRNA; Luteolin results in increased expression of GCLC protein [Luteolin results in increased expression of GCLC mRNA] which results in decreased susceptibility to tert-Butylhydroperoxide |
CTD |
PMID:22864849 |
|
NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970
|
|
G |
GCLM |
glutamate-cysteine ligase modifier subunit |
increases expression |
ISO |
Luteolin results in increased expression of GCLM mRNA; Luteolin results in increased expression of GCLM protein |
CTD |
PMID:22864849 |
|
NCBI chr 1:93,885,199...93,910,370
Ensembl chr 1:93,885,199...93,909,456
|
|
G |
GFAP |
glial fibrillary acidic protein |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Carbon Tetrachloride results in increased expression of GFAP protein] |
CTD |
PMID:19747501 |
|
NCBI chr17:44,903,159...44,915,552
Ensembl chr17:44,903,159...44,916,937
|
|
G |
GPX1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[Luteolin co-treated with 4(G)-alpha-glucopyranosyl-rutin] inhibits the reaction [Doxorubicin results in decreased activity of GPX1 protein] |
CTD |
PMID:9242351 |
|
NCBI chr 3:49,357,176...49,358,353
Ensembl chr 3:49,357,176...49,358,358
|
|
G |
HBEGF |
heparin binding EGF like growth factor |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Sodium Chloride results in increased expression of HBEGF mRNA] |
CTD |
PMID:26800359 |
|
NCBI chr 5:140,332,843...140,346,603
Ensembl chr 5:140,332,843...140,346,603
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
multiple interactions decreases activity |
EXP |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of HIF1A mRNA]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of HIF1A protein]; Luteolin inhibits the reaction [Oxygen deficiency results in increased activity of HIF1A protein]; Luteolin promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Luteolin results in increased expression of and results in increased activity of HIF1A protein Luteolin results in decreased activity of HIF1A protein |
CTD |
PMID:19958256 PMID:20153296 PMID:25448439 |
|
NCBI chr14:61,695,513...61,748,259
Ensembl chr14:61,695,513...61,748,259
|
|
G |
HMOX1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
Luteolin inhibits the reaction [Vehicle Emissions analog results in increased expression of HMOX1 protein] Luteolin results in increased expression of HMOX1 protein Luteolin results in increased expression of HMOX1 mRNA; Luteolin results in increased expression of HMOX1 protein [Luteolin results in increased expression of HMOX1 mRNA] which results in decreased susceptibility to tert-Butylhydroperoxide |
CTD |
PMID:10975858 PMID:22864849 PMID:32268164 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,207 Ensembl chr22:35,380,361...35,394,207
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP ISO |
Luteolin inhibits the reaction [Tunicamycin results in increased expression of HSPA5 mRNA] Luteolin inhibits the reaction [Tunicamycin results in increased expression of HSPA5 mRNA]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of HSPA5 protein] |
CTD |
PMID:32407927 |
|
NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,343
|
|
G |
ICAM1 |
intercellular adhesion molecule 1 |
multiple interactions |
EXP |
Luteolin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:15113938 PMID:15322261 |
|
NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615
|
|
G |
IFNB1 |
interferon beta 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA] |
CTD |
PMID:19426678 |
|
NCBI chr 9:21,077,104...21,077,942
Ensembl chr 9:21,077,104...21,077,942
|
|
G |
IFNG |
interferon gamma |
increases expression multiple interactions |
ISO |
Luteolin results in increased expression of IFNG protein Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] affects the localization of and results in increased activity of NFKB1 protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] affects the localization of and results in increased activity of RELA protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in decreased secretion of INS1 protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased degradation of NFKBIA protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 protein] |
CTD |
PMID:12755373 PMID:18090225 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IL10 |
interleukin 10 |
multiple interactions |
ISO EXP |
Luteolin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] Luteolin inhibits the reaction [nickel chloride results in increased expression of IL10 protein] |
CTD |
PMID:16934226 PMID:30016632 |
|
NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
|
|
G |
IL12B |
interleukin 12B |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IL12B mRNA] |
CTD |
PMID:19426678 |
|
NCBI chr 5:159,314,780...159,330,487
Ensembl chr 5:159,314,780...159,330,487 Ensembl chr 5:159,314,780...159,330,487
|
|
G |
IL13 |
interleukin 13 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Calcimycin results in increased expression of IL13 mRNA] |
CTD |
PMID:17950587 |
|
NCBI chr 5:132,656,522...132,661,110
Ensembl chr 5:132,656,263...132,661,110
|
|
G |
IL17A |
interleukin 17A |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of IL17A protein] |
CTD |
PMID:25450234 |
|
NCBI chr 6:52,186,375...52,190,638
Ensembl chr 6:52,186,375...52,190,638
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
EXP ISO |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased secretion of IL1B protein]; Luteolin inhibits the reaction [Glucose results in increased expression of IL1B mRNA]; Luteolin inhibits the reaction [Glucose results in increased expression of IL1B protein]; Luteolin inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Luteolin inhibits the reaction [IL1B protein results in increased secretion of IL6 protein]; Luteolin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL1B protein]; Luteolin inhibits the reaction [nickel chloride results in increased expression of IL1B protein] Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] affects the localization of and results in increased activity of NFKB1 protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] affects the localization of and results in increased activity of RELA protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in decreased secretion of INS1 protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased degradation of NFKBIA protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; Luteolin inhibits the reaction [cobaltous chloride results in increased expression of IL1B protein]; Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of IL1B protein]; Luteolin inhibits the reaction [lipoteichoic acid results in increased expression of IL1B] |
CTD |
PMID:18090225 PMID:18946510 PMID:19557821 PMID:20685402 PMID:24134915 PMID:25448439 PMID:25450234 PMID:30016632 PMID:31362009 |
|
NCBI chr 2:112,829,751...112,836,843
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL27 |
interleukin 27 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of IL27 mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IL27 mRNA] |
CTD |
PMID:19426678 |
|
NCBI chr16:28,499,362...28,526,730
Ensembl chr16:28,499,362...28,512,051
|
|
G |
IL3 |
interleukin 3 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Calcimycin results in increased expression of IL3 mRNA] |
CTD |
PMID:17950587 |
|
NCBI chr 5:132,060,655...132,063,204
Ensembl chr 5:132,060,655...132,063,204
|
|
G |
IL4 |
interleukin 4 |
multiple interactions decreases expression |
EXP ISO |
Luteolin inhibits the reaction [[Calcimycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL4] Luteolin inhibits the reaction [Calcimycin results in increased expression of IL4 mRNA] Luteolin results in decreased expression of IL4 protein |
CTD |
PMID:12755373 PMID:16343431 PMID:16601352 PMID:17950587 |
|
NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678
|
|
G |
IL5 |
interleukin 5 |
decreases expression |
ISO |
Luteolin results in decreased expression of IL5 protein |
CTD |
PMID:12755373 |
|
NCBI chr 5:132,539,194...132,556,864
Ensembl chr 5:132,541,445...132,556,838
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
EXP ISO |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased secretion of IL6 protein]; Luteolin inhibits the reaction [IL1B protein results in increased secretion of IL6 protein]; Luteolin inhibits the reaction [nickel chloride results in increased expression of IL6 protein] Luteolin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL6 protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of IL6 protein] Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of IL6 protein] |
CTD |
PMID:11123379 PMID:18720166 PMID:19426678 PMID:24134915 PMID:25448439 PMID:25450234 PMID:30016632 |
|
NCBI chr 7:22,725,889...22,732,002
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
INSR |
insulin receptor |
multiple interactions |
ISO |
Luteolin inhibits the reaction [INS1 protein results in increased phosphorylation of INSR protein] |
CTD |
PMID:18591783 |
|
NCBI chr19:7,112,257...7,294,414
Ensembl chr19:7,112,255...7,294,414
|
|
G |
IRF3 |
interferon regulatory factor 3 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Lipopolysaccharides promotes the reaction [IRF3 protein binds to IRF3 protein]]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of IRF3 protein] |
CTD |
PMID:19426678 |
|
NCBI chr19:49,659,572...49,665,857
Ensembl chr19:49,659,569...49,665,875
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases phosphorylation |
EXP ISO |
Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of JUN protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of [FOS protein binds to JUN protein]]; Luteolin inhibits the reaction [TNF protein results in increased expression of JUN mRNA]; Luteolin promotes the reaction [TNF protein results in increased phosphorylation of JUN protein]; Luteolin results in decreased phosphorylation of and results in decreased activity of JUN protein Luteolin results in decreased phosphorylation of JUN protein |
CTD |
PMID:15322261 PMID:15334063 PMID:16343431 PMID:17950587 PMID:30133131 |
|
NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,780,791...58,784,047 Ensembl chr 1:58,780,791...58,784,047
|
|
G |
JUNB |
JunB proto-oncogene, AP-1 transcription factor subunit |
decreases activity |
EXP |
Luteolin results in decreased activity of JUNB protein |
CTD |
PMID:16343431 |
|
NCBI chr19:12,791,486...12,793,315
Ensembl chr19:12,791,486...12,793,315
|
|
G |
JUND |
JunD proto-oncogene, AP-1 transcription factor subunit |
decreases activity |
EXP |
Luteolin results in decreased activity of JUND protein |
CTD |
PMID:16343431 |
|
NCBI chr19:18,279,694...18,281,622
Ensembl chr19:18,279,694...18,281,622
|
|
G |
MAOA |
monoamine oxidase A |
decreases activity multiple interactions |
EXP ISO |
Luteolin results in decreased activity of MAOA protein Luteolin inhibits the reaction [[MAOA protein results in increased metabolism of Serotonin] which results in increased abundance of hydroxyindoleacetaldehyde]; Luteolin inhibits the reaction [MAOA protein results in increased abundance of hydroxyindoleacetaldehyde]; Luteolin inhibits the reaction [MAOA protein results in increased metabolism of Serotonin] |
CTD |
PMID:23009399 |
|
NCBI chr X:43,655,006...43,746,817
Ensembl chr X:43,654,907...43,746,824
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
multiple interactions |
EXP |
Luteolin results in increased expression of and results in increased lipidation of MAP1LC3B protein; PD 0325901 inhibits the reaction [Luteolin results in increased expression of and results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:32268164 |
|
NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions decreases phosphorylation increases phosphorylation increases activity |
EXP ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in increased phosphorylation of MAPK1 protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of MAPK1 protein]; Luteolin inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of MAPK1 protein]; Luteolin results in decreased phosphorylation of and results in decreased activity of MAPK1 protein; PD 0325901 inhibits the reaction [Luteolin results in increased phosphorylation of MAPK1 protein] Luteolin results in decreased phosphorylation of MAPK1 protein Luteolin results in increased activity of MAPK1 protein |
CTD |
PMID:10718847 PMID:15322261 PMID:17950587 PMID:17982879 PMID:19344998 PMID:19557821 PMID:22864849 PMID:25448439 PMID:27474067 PMID:32268164 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,754,500...21,867,680 Ensembl chr22:21,754,500...21,867,680
|
|
G |
MAPK10 |
mitogen-activated protein kinase 10 |
increases phosphorylation |
EXP |
Luteolin results in increased phosphorylation of MAPK10 protein |
CTD |
PMID:21601631 |
|
NCBI chr 4:86,010,405...86,594,625
Ensembl chr 4:85,990,007...86,594,625
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions decreases phosphorylation increases phosphorylation increases activity |
EXP ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in increased phosphorylation of MAPK3 protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of MAPK3 protein]; Luteolin inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein]; Luteolin results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; PD 0325901 inhibits the reaction [Luteolin results in increased phosphorylation of MAPK3 protein] Luteolin results in decreased phosphorylation of MAPK3 protein Luteolin inhibits the reaction [lipoteichoic acid results in increased phosphorylation of MAPK3 protein]; Luteolin results in decreased phosphorylation of and results in decreased activity of MAPK3 protein Luteolin results in increased activity of MAPK3 protein |
CTD |
PMID:10718847 PMID:17950587 PMID:17982879 PMID:19344998 PMID:19557821 PMID:20685402 PMID:25448439 PMID:27474067 PMID:32268164 |
|
NCBI chr16:30,114,105...30,123,309
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
EXP |
Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK8 protein]; Luteolin promotes the reaction [TNF protein results in increased phosphorylation of MAPK8 protein]; Luteolin results in decreased phosphorylation of and results in decreased activity of MAPK8 protein Luteolin results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:10718847 PMID:15334063 PMID:21601631 PMID:30133131 |
|
NCBI chr10:48,306,673...48,439,360
Ensembl chr10:48,306,639...48,439,360
|
|
G |
MAPK9 |
mitogen-activated protein kinase 9 |
increases phosphorylation multiple interactions |
EXP |
Luteolin results in increased phosphorylation of MAPK9 protein Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:21601631 PMID:30133131 |
|
NCBI chr 5:180,233,143...180,292,083
Ensembl chr 5:180,233,143...180,292,099
|
|
G |
MDM2 |
MDM2 proto-oncogene |
multiple interactions |
ISO |
Luteolin promotes the reaction [Hydrogen Peroxide results in increased expression of MDM2 mRNA] |
CTD |
PMID:27525270 |
|
NCBI chr12:68,808,149...68,850,686
Ensembl chr12:68,808,177...68,850,686
|
|
G |
MMP1 |
matrix metallopeptidase 1 |
decreases expression |
EXP |
Luteolin results in decreased expression of MMP1 mRNA; Luteolin results in decreased expression of MMP1 protein |
CTD |
PMID:21112745 |
|
NCBI chr11:102,789,919...102,798,160
Ensembl chr11:102,789,919...102,798,160
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
multiple interactions increases expression decreases secretion |
EXP ISO |
Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of MMP9 protein]; Luteolin inhibits the reaction [EGF protein results in increased secretion of MMP9 protein] Luteolin results in increased expression of MMP9 protein Luteolin inhibits the reaction [Carbon Tetrachloride results in decreased expression of MMP9 protein] Luteolin results in decreased secretion of MMP9 protein |
CTD |
PMID:10556937 PMID:15135307 PMID:19747501 PMID:25448439 PMID:30133131 |
|
NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
|
|
G |
NFAT5 |
nuclear factor of activated T cells 5 |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Sodium Chloride results in increased expression of NFAT5 mRNA] |
CTD |
PMID:26800359 |
|
NCBI chr16:69,565,952...69,704,654
Ensembl chr16:69,565,094...69,704,666
|
|
G |
NFE2L2 |
nuclear factor, erythroid 2 like 2 |
multiple interactions increases activity |
ISO EXP |
[Luteolin results in increased activity of NFE2L2 protein] which results in decreased susceptibility to 1-Methyl-4-phenylpyridinium; Luteolin affects the localization of and results in increased activity of NFE2L2 protein [Luteolin results in increased phosphorylation of and affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of SESN2 mRNA; Luteolin results in increased phosphorylation of and affects the localization of and results in increased activity of NFE2L2 protein |
CTD |
PMID:17982879 PMID:22864849 PMID:32407927 |
|
NCBI chr 2:177,230,303...177,265,131
Ensembl chr 2:177,227,595...177,392,697
|
|
G |
NFKB1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP ISO |
Luteolin inhibits the reaction [TNF protein results in increased activity of NFKB1 protein] Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] affects the localization of and results in increased activity of NFKB1 protein] |
CTD |
PMID:15334063 PMID:18090225 |
|
NCBI chr 4:102,501,266...102,617,302
Ensembl chr 4:102,501,331...102,617,302
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
multiple interactions |
EXP ISO |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased degradation of NFKBIA protein]; Luteolin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of NFKBIA protein]; Luteolin inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Luteolin inhibits the reaction [TNF protein results in increased phosphorylation of [NFKBIB protein binds to NFKBIA protein]] Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased degradation of NFKBIA protein] Luteolin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in decreased expression of and results in increased phosphorylation of NFKBIA protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:11123379 PMID:15322261 PMID:16934226 PMID:18090225 PMID:19557821 PMID:25448439 |
|
NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,511...35,404,749 Ensembl chr14:35,401,511...35,404,749
|
|
G |
NFKBIB |
NFKB inhibitor beta |
multiple interactions |
EXP |
Luteolin inhibits the reaction [TNF protein results in increased phosphorylation of [NFKBIB protein binds to NFKBIA protein]] |
CTD |
PMID:15322261 |
|
NCBI chr19:38,899,503...38,908,894
Ensembl chr19:38,899,700...38,908,893
|
|
G |
NLRP1 |
NLR family pyrin domain containing 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of NLRP1A protein] |
CTD |
PMID:25450234 |
|
NCBI chr17:5,501,396...5,584,509
Ensembl chr17:5,499,427...5,619,424
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of NOS2 mRNA]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of NOS2 protein] Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 protein] |
CTD |
PMID:16934226 PMID:18090225 PMID:19426678 PMID:25448439 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NOS3 |
nitric oxide synthase 3 |
multiple interactions |
ISO |
[Luteolin co-treated with linarin] results in increased expression of NOS3 protein modified form |
CTD |
PMID:29052401 |
|
NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588
|
|
G |
NR1D1 |
nuclear receptor subfamily 1 group D member 1 |
decreases expression |
EXP |
Luteolin results in decreased expression of NR1D1 mRNA |
CTD |
PMID:19397994 |
|
NCBI chr17:40,092,793...40,100,589
Ensembl chr17:40,092,793...40,100,589
|
|
G |
P2RX4 |
purinergic receptor P2X 4 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of P2RX4 protein] |
CTD |
PMID:25450234 |
|
NCBI chr12:121,210,096...121,234,106
Ensembl chr12:121,209,861...121,234,106 Ensembl chr12:121,209,861...121,234,106
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
EXP ISO |
[Luteolin co-treated with Paclitaxel] results in decreased expression of PARP1 protein; PD 0325901 promotes the reaction [Luteolin results in increased cleavage of PARP1 protein] Luteolin inhibits the reaction [Tunicamycin results in increased expression of PARP1 protein modified form] |
CTD |
PMID:12168845 PMID:24525192 PMID:32268164 PMID:32407927 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,691...226,408,093 Ensembl chr 1:226,360,691...226,408,093
|
|
G |
PDGFB |
platelet derived growth factor subunit B |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Methamphetamine results in increased expression of PDGFB mRNA] |
CTD |
PMID:32035215 |
|
NCBI chr22:39,223,359...39,244,982
Ensembl chr22:39,223,359...39,244,982
|
|
G |
PKM |
pyruvate kinase M1/2 |
increases activity |
EXP |
Luteolin results in increased activity of PKM protein |
CTD |
PMID:25388478 |
|
NCBI chr15:72,199,029...72,231,389
Ensembl chr15:72,199,029...72,231,822
|
|
G |
PLK1 |
polo like kinase 1 |
decreases expression |
EXP |
Luteolin results in decreased expression of PLK1 protein |
CTD |
PMID:22926442 |
|
NCBI chr16:23,678,889...23,690,367
Ensembl chr16:23,677,656...23,690,367
|
|
G |
PRKCA |
protein kinase C alpha |
multiple interactions |
EXP |
Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PRKCA protein] |
CTD |
PMID:30133131 |
|
NCBI chr17:66,302,613...66,810,743
Ensembl chr17:66,302,613...66,810,743
|
|
G |
PSCA |
prostate stem cell antigen |
decreases expression |
EXP |
Luteolin results in decreased expression of PSCA mRNA |
CTD |
PMID:18331776 PMID:19397994 |
|
NCBI chr 8:142,670,297...142,682,725
Ensembl chr 8:142,670,308...142,682,725
|
|
G |
PTEN |
phosphatase and tensin homolog |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Methamphetamine results in increased expression of PTEN protein] |
CTD |
PMID:32035215 |
|
NCBI chr10:87,863,625...87,971,930
Ensembl chr10:87,863,625...87,971,930
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP ISO |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of PTGS2 protein]; Luteolin inhibits the reaction [Dust analog results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Dust results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Glucose results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Glucose results in increased expression of PTGS2 protein]; Luteolin inhibits the reaction [Particulate Matter analog results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Particulate Matter results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Vehicle Emissions analog results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Vehicle Emissions results in increased expression of PTGS2 mRNA] Luteolin inhibits the reaction [Cisplatin results in increased expression of PTGS2 protein] |
CTD |
PMID:16263508 PMID:19557821 PMID:23770416 PMID:25448439 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,423
|
|
G |
PTK2 |
protein tyrosine kinase 2 |
multiple interactions decreases phosphorylation |
EXP |
EGF protein inhibits the reaction [Luteolin results in decreased phosphorylation of PTK2 protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of PTK2 protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:15135307 PMID:25448439 |
|
NCBI chr 8:140,657,900...141,002,079
Ensembl chr 8:140,657,900...141,002,216
|
|
G |
PYCARD |
PYD and CARD domain containing |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of PYCARD protein] |
CTD |
PMID:25450234 |
|
NCBI chr16:31,201,486...31,202,760
Ensembl chr16:31,201,486...31,203,450
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of RELA protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased activity of and affects the localization of RELA protein]; Luteolin inhibits the reaction [Glucose affects the localization of RELA protein]; Luteolin inhibits the reaction [TNF protein affects the localization of RELA protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of RELA protein] Luteolin inhibits the reaction [Cisplatin results in increased expression of RELA protein] Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] affects the localization of and results in increased activity of RELA protein] |
CTD |
PMID:15113938 PMID:15334063 PMID:18090225 PMID:19557821 PMID:23770416 PMID:25448439 PMID:30133131 |
|
NCBI chr11:65,653,601...65,662,946
Ensembl chr11:65,653,597...65,663,090
|
|
G |
SELE |
selectin E |
multiple interactions |
EXP |
Luteolin inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:15113938 |
|
NCBI chr 1:169,722,640...169,734,079
Ensembl chr 1:169,722,640...169,764,705
|
|
G |
SESN2 |
sestrin 2 |
multiple interactions increases expression |
ISO EXP |
Luteolin inhibits the reaction [Tunicamycin results in increased expression of SESN2 mRNA]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of SESN2 protein] [Luteolin results in increased phosphorylation of and affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of SESN2 mRNA; SESN2 protein promotes the reaction [Luteolin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]] Luteolin results in increased expression of SESN2 mRNA; Luteolin results in increased expression of SESN2 protein |
CTD |
PMID:32407927 |
|
NCBI chr 1:28,259,452...28,282,491
Ensembl chr 1:28,259,518...28,282,491
|
|
G |
SFN |
stratifin |
increases expression |
EXP |
Luteolin results in increased expression of SFN mRNA; Luteolin results in increased expression of SFN protein |
CTD |
PMID:18331776 |
|
NCBI chr 1:26,863,149...26,864,456
Ensembl chr 1:26,863,149...26,864,456
|
|
G |
SLC16A1 |
solute carrier family 16 member 1 |
multiple interactions |
ISO |
[[Luteolin co-treated with Phloretin] results in decreased activity of SLC16A1 protein] which results in decreased uptake of Sodium Oxybate; [Luteolin results in decreased activity of SLC16A1 protein] which results in decreased uptake of Sodium Oxybate |
CTD |
PMID:17108059 |
|
NCBI chr 1:112,911,847...112,956,196
Ensembl chr 1:112,911,847...112,957,013
|
|
G |
SLC22A6 |
solute carrier family 22 member 6 |
decreases activity |
EXP |
Luteolin results in decreased activity of SLC22A6 protein |
CTD |
PMID:32159797 |
|
NCBI chr11:62,976,597...62,984,967
Ensembl chr11:62,936,385...62,984,967 Ensembl chr11:62,936,385...62,984,967
|
|
G |
SLC22A8 |
solute carrier family 22 member 8 |
decreases activity |
EXP |
Luteolin results in decreased activity of SLC22A8 protein |
CTD |
PMID:32159797 |
|
NCBI chr11:62,992,824...63,015,841
Ensembl chr11:62,989,154...63,015,841
|
|
G |
SLC2A3 |
solute carrier family 2 member 3 |
multiple interactions |
EXP |
[Luteolin co-treated with Oxygen deficiency] results in decreased expression of SLC2A3 mRNA |
CTD |
PMID:20153296 |
|
NCBI chr12:7,919,230...7,936,187
Ensembl chr12:7,919,230...7,936,187
|
|
G |
SLC2A4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [INS1 protein affects the localization of SLC2A4 protein] |
CTD |
PMID:18591783 |
|
NCBI chr17:7,281,718...7,288,257
Ensembl chr17:7,281,718...7,288,257
|
|
G |
SLC5A1 |
solute carrier family 5 member 1 |
multiple interactions |
EXP |
Luteolin inhibits the reaction [SLC5A1 protein results in increased uptake of methylglucoside] |
CTD |
PMID:17495124 |
|
NCBI chr22:32,043,050...32,113,029
Ensembl chr22:32,043,261...32,113,029
|
|
G |
SLCO1B1 |
solute carrier organic anion transporter family member 1B1 |
multiple interactions decreases activity |
EXP |
[Luteolin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Fluvastatin |
CTD |
PMID:32259555 |
|
NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
|
|
G |
SOD1 |
superoxide dismutase 1 |
affects activity multiple interactions |
EXP ISO |
Luteolin affects the activity of SOD1 protein Luteolin inhibits the reaction [Carbon Tetrachloride results in increased activity of SOD1 protein] |
CTD |
PMID:18503759 PMID:19747501 |
|
NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,622...31,668,931 Ensembl chr21:31,659,622...31,668,931
|
|
G |
SOD2 |
superoxide dismutase 2 |
increases expression |
EXP |
Luteolin results in increased expression of SOD2 protein |
CTD |
PMID:32268164 |
|
NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529 Ensembl chr 6:159,669,069...159,762,529 Ensembl chr 6:159,669,069...159,762,529
|
|
G |
SREBF1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Tunicamycin results in increased expression of SREBF1 mRNA] |
CTD |
PMID:32407927 |
|
NCBI chr17:17,811,334...17,837,017
Ensembl chr17:17,810,399...17,837,011
|
|
G |
STAT3 |
signal transducer and activator of transcription 3 |
multiple interactions decreases phosphorylation |
EXP |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of STAT3 protein]; Luteolin promotes the reaction [Paclitaxel results in decreased phosphorylation of STAT3 protein]; Paclitaxel promotes the reaction [Luteolin results in decreased phosphorylation of STAT3 protein] |
CTD |
PMID:24525192 PMID:25448439 |
|
NCBI chr17:42,313,324...42,388,502
Ensembl chr17:42,313,324...42,388,482 Ensembl chr17:42,313,324...42,388,482 Ensembl chr17:42,313,324...42,388,482
|
|
G |
TBK1 |
TANK binding kinase 1 |
decreases activity |
EXP |
Luteolin results in decreased activity of TBK1 protein |
CTD |
PMID:19426678 |
|
NCBI chr12:64,452,105...64,502,114
Ensembl chr12:64,452,092...64,502,114 Ensembl chr12:64,452,092...64,502,114
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP ISO |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased secretion of TNF protein]; Luteolin inhibits the reaction [Glucose results in increased expression of TNF mRNA]; Luteolin inhibits the reaction [Glucose results in increased expression of TNF protein]; Luteolin inhibits the reaction [nickel chloride results in increased expression of TNF protein]; Luteolin inhibits the reaction [TNF protein affects the localization of RELA protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of [FOS protein binds to JUN protein]]; Luteolin inhibits the reaction [TNF protein results in increased activity of MAPK1 protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of RELA protein]; Luteolin inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Luteolin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein]; Luteolin inhibits the reaction [TNF protein results in increased expression of FOS mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Luteolin inhibits the reaction [TNF protein results in increased expression of JUN mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of SELE protein]; Luteolin inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein]; Luteolin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; Luteolin inhibits the reaction [TNF protein results in increased phosphorylation of [NFKBIB protein binds to NFKBIA protein]]; Luteolin promotes the reaction [TNF protein results in increased cleavage of and results in increased activity of CASP8 protein]; Luteolin promotes the reaction [TNF protein results in increased phosphorylation of JUN protein]; Luteolin promotes the reaction [TNF protein results in increased phosphorylation of MAPK8 protein] Luteolin inhibits the reaction [Cisplatin results in increased expression of TNF protein]; Luteolin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Luteolin inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of IL6 protein] Luteolin inhibits the reaction [Calcimycin results in increased expression of TNF mRNA]; Luteolin inhibits the reaction [cobaltous chloride results in increased expression of TNF protein]; Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of TNF protein] |
CTD |
PMID:11123379 PMID:15113938 PMID:15322261 PMID:15334063 PMID:16934226 PMID:17950587 PMID:18720166 PMID:19426678 PMID:19557821 PMID:23770416 PMID:25448439 PMID:25450234 PMID:30016632 PMID:31362009 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TNFAIP3 |
TNF alpha induced protein 3 |
multiple interactions |
EXP |
Luteolin inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein] |
CTD |
PMID:15334063 |
|
NCBI chr 6:137,866,317...137,883,312
Ensembl chr 6:137,867,214...137,883,312
|
|
G |
TNFSF10 |